{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Pro\\Stages\\A4 - DVRC\\Work\\Supervised-Learning-using-Unsupervised-Learning-Metrics-in-the-absence-of-Annotated-Data\\.venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from custom_score.score import score\n",
    "from custom_score.utils import serialized_to_model\n",
    "\n",
    "from custom_score.refine import Refiner\n",
    "import tensorflow_datasets as tfds\n",
    "import numpy as np"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Basic Test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "w2v = serialized_to_model(r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Models\\serialized_w2v.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "billsum0 = \"SECTION 1. SHORT TITLE.\\n\\n    This Act may be cited as the ``National Science Education Tax \\nIncentive for Businesses Act of 2007''.\\n\\nSEC. 2. CREDITS FOR CERTAIN CONTRIBUTIONS BENEFITING SCIENCE, \\n              TECHNOLOGY, ENGINEERING, AND MATHEMATICS EDUCATION AT THE \\n              ELEMENTARY AND SECONDARY SCHOOL LEVEL.\\n\\n    (a) In General.--Subpart D of part IV of subchapter A of chapter 1 \\nof the Internal Revenue Code of 1986 (relating to business related \\ncredits) is amended by adding at the end the following new section:\\n\\n``SEC. 45O. CONTRIBUTIONS BENEFITING SCIENCE, TECHNOLOGY, ENGINEERING, \\n              AND MATHEMATICS EDUCATION AT THE ELEMENTARY AND SECONDARY \\n              SCHOOL LEVEL.\\n\\n    ``(a) In General.--For purposes of section 38, the elementary and \\nsecondary science, technology, engineering, and mathematics (STEM) \\ncontributions credit determined under this section for the taxable year \\nis an amount equal to 100 percent of the qualified STEM contributions \\nof the taxpayer for such taxable year.\\n    ``(b) Qualified STEM Contributions.--For purposes of this section, \\nthe term `qualified STEM contributions' means--\\n            ``(1) STEM school contributions,\\n            ``(2) STEM teacher externship expenses, and\\n            ``(3) STEM teacher training expenses.\\n    ``(c) STEM School Contributions.--For purposes of this section--\\n            ``(1) In general.--The term `STEM school contributions' \\n        means--\\n                    ``(A) STEM property contributions, and\\n                    ``(B) STEM service contributions.\\n            ``(2) STEM property contributions.--The term `STEM property \\n        contributions' means the amount which would (but for subsection \\n        (f)) be allowed as a deduction under section 170 for a \\n        charitable contribution of STEM inventory property if--\\n                    ``(A) the donee is an elementary or secondary \\n                school described in section 170(b)(1)(A)(ii),\\n                    ``(B) substantially all of the use of the property \\n                by the donee is within the United States or within the \\n                defense dependents' education system for educational \\n                purposes in any of the grades K-12 that are related to \\n                the purpose or function of the donee,\\n                    ``(C) the original use of the property begins with \\n                the donee,\\n                    ``(D) the property will fit productively into the \\n                donee's education plan,\\n                    ``(E) the property is not transferred by the donee \\n                in exchange for money, other property, or services, \\n                except for shipping, installation and transfer costs, \\n                and\\n                    ``(F) the donee's use and disposition of the \\n                property will be in accordance with the provisions of \\n                subparagraphs (B) and (E).\\n        The determination of the amount of deduction under section 170 \\n        for purposes of this paragraph shall be made as if the \\n        limitation under section 170(e)(3)(B) applied to all STEM \\n        inventory property.\\n            ``(3) STEM service contributions.--The term `STEM service \\n        contributions' means the amount paid or incurred during the \\n        taxable year for STEM services provided in the United States or \\n        in the defense dependents' education system for the exclusive \\n        benefit of students at an elementary or secondary school \\n        described in section 170(b)(1)(A)(ii) but only if--\\n                    ``(A) the taxpayer is engaged in the trade or \\n                business of providing such services on a commercial \\n                basis, and\\n                    ``(B) no charge is imposed for providing such \\n                services.\\n            ``(4) STEM inventory property.--The term `STEM inventory \\n        property' means, with respect to any contribution to a school, \\n        any property--\\n                    ``(A) which is described in paragraph (1) or (2) of \\n                section 1221(a) with respect to the donor, and\\n                    ``(B) which is determined by the school to be \\n                needed by the school in providing education in grades \\n                K-12 in the areas of science, technology, engineering, \\n                or mathematics.\\n            ``(5) STEM services.--The term `STEM services' means, with \\n        respect to any contribution to a school, any service determined \\n        by the school to be needed by the school in providing education \\n        in grades K-12 in the areas of science, technology, \\n        engineering, or mathematics, including teaching courses of \\n        instruction at such school in any such area.\\n            ``(6) Defense dependents' education system.--For purposes \\n        of this subsection, the term `defense dependents' education \\n        system' means the program established and operated under the \\n        Defense Dependents' Education Act of 1978 (20 U.S.C. 921 et \\n        seq.).\\n    ``(d) STEM Teacher Externship Expenses.--For purposes of this \\nsection--\\n            ``(1) In general.--The term `STEM teacher externship \\n        expenses' means any amount paid or incurred to carry out a STEM \\n        externship program of the taxpayer but only to the extent that \\n        such amount is attributable to the participation in such \\n        program of any eligible STEM teacher, including amounts paid to \\n        such a teacher as a stipend while participating in such \\n        program.\\n            ``(2) STEM externship program.--The term `STEM externship \\n        program' means any program--\\n                    ``(A) established by a taxpayer engaged in a trade \\n                or business within an area of science, technology, \\n                engineering, or mathematics, and\\n                    ``(B) under which eligible STEM teachers receive \\n                training to enhance their teaching skills in the areas \\n                of science, technology, engineering, or mathematics or \\n                otherwise improve their knowledge in such areas.\\n            ``(3) Eligible stem teacher.--The term `eligible STEM \\n        teacher' means any individual--\\n                    ``(A) who is a teacher in grades K-12 at an \\n                educational organization described in section \\n                170(b)(1)(A)(ii) which is located in the United States \\n                or which is located on a United States military base \\n                outside the United States, and\\n                    ``(B) whose teaching responsibilities at such \\n                school include, or are likely to include, any course in \\n                the areas of science, technology, engineering, or \\n                mathematics.\\n    ``(e) STEM Teacher Training Expenses.--The term `STEM teacher \\ntraining expenses' means any amount paid or incurred by a taxpayer \\nengaged in a trade or business within an area of science, technology, \\nengineering, or mathematics which is attributable to the participation \\nof any eligible STEM teacher in a regular training program provided to \\nemployees of the taxpayer which is determined by such teacher's school \\nas enhancing such teacher's teaching skills in the areas of science, \\ntechnology, engineering, or mathematics.\\n    ``(f) Denial of Double Benefit.--No deduction shall be allowed \\nunder this chapter for any amount allowed as a credit under this \\nsection.''.\\n    (b) Conforming Amendments.--\\n            (1) Section 38(b) of such Code is amended by striking \\n        ``plus'' at the end of paragraph (30), by striking the period \\n        at the end of paragraph (31), and inserting ``, plus'', and by \\n        adding at the end the following new paragraph:\\n            ``(32) the elementary and secondary science, technology, \\n        engineering, and mathematics (STEM) contributions credit \\n        determined under section 45O.''.\\n            (2) The table of sections for subpart D of part IV of \\n        subchapter A of chapter 1 of such Code is amended by adding at \\n        the end the following new item:\\n\\n``Sec. 45O. Contributions benefiting science, technology, engineering, \\n                            and mathematics education at the elementary \\n                            and secondary school level.''.\\n    (c) Effective Date.--The amendments made by this section shall \\napply to taxable years beginning after the date of the enactment of \\nthis Act.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "s = Refiner([billsum0, billsum0], w2v, reductionFactor=4, maxSpacing=15)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "s.refine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(\"len simplified: \", len(s.refined[0]), \" || \", \"len initial: \", len(s.corpus[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res = s.assess()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"scores\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"correlations\"]"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Assess function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from rouge_score import rouge_scorer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from scipy.stats import pearsonr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def assess(simp, verbose=True):\n",
    "    \"\"\"\n",
    "    Assesses quality of the simplified corpus by computing Static BERTscore and Rouge-Score on the simplified version compared to it's initial version.\n",
    "\n",
    "    :param1 self (Simplifier): Simplifier Object (see __init__ function for more details).\n",
    "    :param2 verbose (Boolean): When put to true, assess results will be printed.\n",
    "\n",
    "    :output (dict): Dictionnary containing both the scores of Static BERTScore and Rouge as well as their correlation\n",
    "    \"\"\"\n",
    "    assert simp.simplified != None, \"simplified corpus doesn't exists\"\n",
    "\n",
    "    #Static BERTScore computation\n",
    "    customScore = score(simp.model, simp.simplified, simp.corpus)\n",
    "\n",
    "    #Rouge-Score computation\n",
    "    rougeScorer = rouge_scorer.RougeScorer(['rouge1', 'rougeL'], use_stemmer=True)\n",
    "    rougeScore = [rougeScorer.score(s, c) for s, c in zip(simp.simplified, simp.corpus)]\n",
    "\n",
    "    #Data formating\n",
    "    custom_R = [round(t[0], 2) for t in customScore]\n",
    "    rouge1_R = [round(t['rouge1'][0], 2) for t in rougeScore]\n",
    "    rougeL_R = [round(t['rougeL'][0], 2) for t in rougeScore]\n",
    "\n",
    "    dfCustom = pd.DataFrame({'CBERT' : custom_R,\n",
    "                             'R-1' : rouge1_R,\n",
    "                             'R-L' : rougeL_R\n",
    "                             })\n",
    "\n",
    "    #Correlation estimation\n",
    "    pearsonCor_c_r1 = pearsonr(custom_R, rouge1_R)\n",
    "    pearsonCor_c_rl = pearsonr(custom_R, rougeL_R)\n",
    "\n",
    "    dfCor = pd.DataFrame({'pearson_CBERT_R-1' : pearsonCor_c_r1,\n",
    "                          'pearson_CBERT_R-L' : pearsonCor_c_rl}, index=[\"Pearson score\", \"p-value\"])\n",
    "\n",
    "    return {\"scores\": dfCustom, \"correlations\": dfCor}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res = assess(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"scores\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"correlations\"]"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### STR function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "w2v = serialized_to_model(r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Models\\serialized_w2v.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "billsum0 = \"SECTION 1. SHORT TITLE.\\n\\n    This Act may be cited as the ``National Science Education Tax \\nIncentive for Businesses Act of 2007''.\\n\\nSEC. 2. CREDITS FO\" \\\n",
    "            \"R CERTAIN CONTRIBUTIONS BENEFITING SCIENCE, \\n              TECHNOLOGY, ENGINEERING, AND MATHEMATICS EDUCATION AT THE \\n              ELEMENTARY AND SECONDARY \"\\\n",
    "            \"SCHOOL LEVEL.\\n\\n    (a) In General.--Subpart D of part IV of subchapter A of chapter 1 \\nof the Internal Revenue Code of 1986 (relating to business related \\nc\"\\\n",
    "            \"redits) is amended by adding at the end the following new section:\\n\\n``SEC. 45O. CONTRIBUTIONS BENEFITING SCIENCE, TECHNOLOGY, ENGINEERING, \\n              AND MA\"\\\n",
    "            \"THEMATICS EDUCATION AT THE ELEMENTARY AND SECONDARY \\n              SCHOOL LEVEL.\\n\\n    ``(a) In General.--For purposes of section 38, the elementary and \\nsecond\"\\\n",
    "            \"ary science, technology, engineering, and mathematics (STEM) \\ncontributions credit determined under this section for the taxable year \\nis an amount equal to 100 \"\\\n",
    "            \"percent of the qualified STEM contributions \\nof the taxpayer for such taxable year.\\n    ``(b) Qualified STEM Contributions.--For purposes of this section, \\nthe te\"\\\n",
    "            \"rm `qualified STEM contributions' means--\\n            ``(1) STEM school contributions,\\n            ``(2) STEM teacher externship expenses, and\\n            ``(3) ST\"\\\n",
    "            \"EM teacher training expenses.\\n    ``(c) STEM School Contributions.--For purposes of this section--\\n            ``(1) In general.--The term `STEM school contributions' \"\\\n",
    "            \"\\n        means--\\n                    ``(A) STEM property contributions, and\\n                    ``(B) STEM service contributions.\\n            ``(2) STEM property\"\\\n",
    "            \" contributions.--The term `STEM property \\n        contributions' means the amount which would (but for subsection \\n        (f)) be allowed as a deduction under secti\"\\\n",
    "            \"on 170 for a \\n        charitable contribution of STEM inventory property if--\\n                    ``(A) the donee is an elementary or secondary \\n                \"\\\n",
    "            \"school described in section 170(b)(1)(A)(ii),\\n                    ``(B) substantially all of the use of the property \\n                by the donee is within the\"\\\n",
    "            \" United States or within the \\n                defense dependents' education system for educational \\n                purposes in any of the grades K-12 that \"\\\n",
    "            \"are related to \\n                the purpose or function of the donee,\\n                    ``(C) the original use of the property begins with \\n         \"\\\n",
    "            \"       the donee,\\n                    ``(D) the property will fit productively into the \\n                donee's education plan,\\n                   \"\\\n",
    "            \" ``(E) the property is not transferred by the donee \\n                in exchange for money, other property, or services, \\n                except \"\\\n",
    "            \"for shipping, installation and transfer costs, \\n                and\\n                    ``(F) the donee's use and disposition of the \\n        \"\\\n",
    "            \"        property will be in accordance with the provisions of \\n                subparagraphs (B) and (E).\\n        The determination of the amount of deduct\"\\\n",
    "                \"ion under section 170 \\n        for purposes of this paragraph shall be made as if the \\n        limitation under section 170(e)(3)(B) applied to all STEM \"\\\n",
    "                    \"\\n        inventory property.\\n            ``(3) STEM service contributions.--The term `STEM service \\n        contributions' means the amount paid or inc\"\\\n",
    "                        \"urred during the \\n        taxable year for STEM services provided in the United States or \\n        in the defense dependents' education system for the\"\\\n",
    "                            \" exclusive \\n        benefit of students at an elementary or secondary school \\n        described in section 170(b)(1)(A)(ii) but only if--\\n         \"\\\n",
    "                                \"           ``(A) the taxpayer is engaged in the trade or \\n                business of providing such services on a commercial \\n                bas\"\\\n",
    "                                    \"is, and\\n                    ``(B) no charge is imposed for providing such \\n                services.\\n            ``(4) STEM inventory property.--Th\"\\\n",
    "                                        \"e term `STEM inventory \\n        property' means, with respect to any contribution to a school, \\n        any property--\\n                    ``(A) w\"\\\n",
    "                                            \"hich is described in paragraph (1) or (2) of \\n                section 1221(a) with respect to the donor, and\\n                    ``(B) which is determined by the school to be \\n                needed by the school in providing education in grades \\n                K-12 in the areas of science, technology, engineering, \\n                or mathematics.\\n            ``(5) STEM services.--The term `STEM services' means, with \\n        respect to any contribution to a school, any service determined \\n        by the school to be needed by the school in providing education \\n        in grades K-12 in the areas of science, technology, \\n        engineering, or mathematics, including teaching courses of \\n        instruction at such school in any such area.\\n            ``(6) Defense dependents' education system.--For purposes \\n        of this subsection, the term `defense dependents' education \\n        system' means the program established and operated under the \\n        Defense Dependents' Education Act of 1978 (20 U.S.C. 921 et \\n        seq.).\\n    ``(d) STEM Teacher Externship Expenses.--For purposes of this \\nsection--\\n            ``(1) In general.--The term `STEM teacher externship \\n        expenses' means any amount paid or incurred to carry out a STEM \\n        externship program of the taxpayer but only to the extent that \\n        such amount is attributable to the participation in such \\n        program of any eligible STEM teacher, including amounts paid to \\n        such a teacher as a stipend while participating in such \\n        program.\\n            ``(2) STEM externship program.--The term `STEM externship \\n        program' means any program--\\n                    ``(A) established by a taxpayer engaged in a trade \\n                or business within an area of science, technology, \\n                engineering, or mathematics, and\\n                    ``(B) under which eligible STEM teachers receive \\n                training to enhance their teaching skills in the areas \\n                of science, technology, engineering, or mathematics or \\n                otherwise improve their knowledge in such areas.\\n            ``(3) Eligible stem teacher.--The term `eligible STEM \\n        teacher' means any individual--\\n                    ``(A) who is a teacher in grades K-12 at an \\n                educational organization described in section \\n                170(b)(1)(A)(ii) which is located in the United States \\n                or which is located on a United States military base \\n                outside the United States, and\\n                    ``(B) whose teaching responsibilities at such \\n                school include, or are likely to include, any course in \\n                the areas of science, technology, engineering, or \\n                mathematics.\\n    ``(e) STEM Teacher Training Expenses.--The term `STEM teacher \\ntraining expenses' means any amount paid or incurred by a taxpayer \\nengaged in a trade or business within an area of science, technology, \\nengineering, or mathematics which is attributable to the participation \\nof any eligible STEM teacher in a regular training program provided to \\nemployees of the taxpayer which is determined by such teacher's school \\nas enhancing such teacher's teaching skills in the areas of science, \\ntechnology, engineering, or mathematics.\\n    ``(f) Denial of Double Benefit.--No deduction shall be allowed \\nunder this chapter for any amount allowed as a credit under this \\nsection.''.\\n    (b) Conforming Amendments.--\\n            (1) Section 38(b) of such Code is amended by striking \\n        ``plus'' at the end of paragraph (30), by striking the period \\n        at the end of paragraph (31), and inserting ``, plus'', and by \\n        adding at the end the following new paragraph:\\n            ``(32) the elementary and secondary science, technology, \\n        engineering, and mathematics (STEM) contributions credit \\n        determined under section 45O.''.\\n            (2) The table of sections for subpart D of part IV of \\n        subchapter A of chapter 1 of such Code is amended by adding at \\n        the end the following new item:\\n\\n``Sec. 45O. Contributions benefiting science, technology, engineering, \\n                            and mathematics education at the elementary \\n                            and secondary school level.''.\\n    (c) Effective Date.--The amendments made by this section shall \\napply to taxable years beginning after the date of the enactment of \\nthis Act.\"\n",
    "s = Refiner([billsum0], w2v, reductionFactor=4, maxSpacing=15)\n",
    "s.simplify()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from colorama import Fore, Style"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def formatHighlight():\n",
    "    print(f\"{Fore.BLUE}Je suis ton pere{Style.RESET_ALL}\")"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Semantic and syntaxique distance"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from custom_score.utils import cleanString, parseScore\n",
    "from custom_score.score import score\n",
    "import numpy as np\n",
    "from random import uniform\n",
    "from custom_score.utils import serialized_to_model\n",
    "import tensorflow_datasets as tfds\n",
    "from numpy.linalg import norm\n",
    "from rouge_score import rouge_scorer\n",
    "from scipy.stats import pearsonr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parseDistances(distances):\n",
    "    \"\"\"\n",
    "    Converts score to a value interpretable as distance (the greatest the value, the greatest the distance).\n",
    "\n",
    "    :param1 distances (List): List of distances values for each sentences of a corpus with respect to all the others sentences.\n",
    "\n",
    "    :output parsedDisctances (List): List of converted distances. \n",
    "    \"\"\"\n",
    "    refDist = distances[0][0]\n",
    "    toPositive = False \n",
    "    toInverse = False\n",
    "\n",
    "    if refDist < 0:\n",
    "        toPositive = True\n",
    "    if refDist >=-1 and refDist <=1:\n",
    "        toInverse = True\n",
    "    \n",
    "    parsedDistances = []\n",
    "    for distance in distances:\n",
    "        parsedDistance = []\n",
    "        for value in distance:\n",
    "            cur = value\n",
    "            if toPositive:\n",
    "                cur = -cur\n",
    "            if toInverse:\n",
    "                try:\n",
    "                    cur = 1/cur\n",
    "                except ZeroDivisionError:\n",
    "                    cur = 1\n",
    "            parsedDistance.append(cur)\n",
    "        parsedDistances.append(parsedDistance)\n",
    "    return parsedDistances"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def sentenceSelection(corpus, scores, distances, reductionFactor=2):\n",
    "    \"\"\"\n",
    "    Returns a list of selected indices of sentence that will constituate the new corpus.\n",
    "\n",
    "    :param1 corpus (list): List of sentences of the reference document.\n",
    "    :param2 scores (list): List of the similarity scores of each sentence of the reference compared to the entire reference document.\n",
    "    :param3 reductionFactor (float or int): Number determining how much the reference text will be shortened. \n",
    "\n",
    "    :output selected_indexes (list): List of indexes of the initial corpus sentences that have been selected.\n",
    "    \"\"\"\n",
    "    totalLength = len(\" \".join(corpus))\n",
    "    targetLength = int(totalLength/reductionFactor)\n",
    "    selected_indexes = []\n",
    "    \n",
    "    randomized_scores = [np.mean([curScore, uniform(0, 1)]) for curScore in scores]\n",
    "    ranking = np.argsort(randomized_scores)[::-1]\n",
    "\n",
    "    selectedLength = 0\n",
    "    selected_indexes = []\n",
    "    current_distance = lambda x: norm([distances[ranking[x]][i] for i in selected_indexes])\n",
    "    cur = 0\n",
    "    while(selectedLength < targetLength):\n",
    "        if cur == 0:\n",
    "            selected_indexes.append(ranking[cur])\n",
    "            selectedLength += len(corpus[ranking[cur]])\n",
    "        else:\n",
    "            updated_scores = [randomized_scores[i]*current_distance(i) for i in range(len(randomized_scores))]\n",
    "            updated_ranking = np.argsort(updated_scores)[::-1]\n",
    "            updated_ranking = [index for index in updated_ranking if index not in selected_indexes]\n",
    "            selected_indexes.append(updated_ranking[0])\n",
    "            selectedLength += len(corpus[updated_ranking[0]])\n",
    "        cur += 1\n",
    "\n",
    "    return selected_indexes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "class Refiner:\n",
    "\n",
    "    def __init__(self, corpus, model, scorer=score, reductionFactor=2, maxSpacing=10):\n",
    "        \"\"\"\n",
    "        Constructor of the Refiner class. Aims at reducing the size and noise of a given independant list of documents.\n",
    "        \n",
    "        :param1 self (Refiner): Object to initialize.\n",
    "        :param2 corpus (List): List of documents to simplify.\n",
    "        :param3 model (Any): Model used to compute scores and create sentence's ranking.\n",
    "        :param4 reductionFactor (float or int): Number determining how much the reference text will be shortened. \n",
    "        :param5 maxSpacing (int): Maximal number of adjacent space to be found and suppressed in the corpus.\n",
    "        \"\"\"\n",
    "        self.corpus = corpus\n",
    "        self.model = model\n",
    "        self.scorer = scorer\n",
    "        self.rf = reductionFactor\n",
    "        self.ms = maxSpacing\n",
    "        self.refined = None\n",
    "\n",
    "    def refine(self):\n",
    "        \"\"\"\n",
    "        Return a reduced string computed using static embedding vectors similarity. Also denoises the data by removing superfluous elements such as \"\\n\" or useless signs.\n",
    "\n",
    "        :param1 self (Refiner): Refiner Object (see __init__ function for more details).\n",
    "\n",
    "        :output refined (string): refined version of the initial document.\n",
    "        \"\"\"\n",
    "        self.refined = []\n",
    "        for indiv in self.corpus:\n",
    "            #preprocess corpus\n",
    "            clean = cleanString(indiv, self.ms)\n",
    "            sentences = clean.split(\".\")\n",
    "            sentences.pop()\n",
    "            temp = []\n",
    "            for sentence in sentences: \n",
    "                if sentence != None and sentence != \"\":\n",
    "                    temp.append(sentence)\n",
    "            sentences = temp\n",
    "            respaced_sentences = []\n",
    "            for sentence in sentences:\n",
    "                if sentence[0] == \" \":\n",
    "                    sentence = sentence[1:]\n",
    "                respaced_sentences.append(sentence)\n",
    "            corpus = \" \".join(respaced_sentences)\n",
    "\n",
    "            #compute ranking\n",
    "            scores = []\n",
    "            for sentence in respaced_sentences:\n",
    "                scoreOut = self.scorer(self.model, [sentence], [indiv])\n",
    "                R = parseScore(scoreOut)\n",
    "                scores.append(R)\n",
    "            \n",
    "            #compute distances\n",
    "            distances = []\n",
    "            for x in range(len(respaced_sentences)):\n",
    "                distance = []\n",
    "                for y in range(len(respaced_sentences)):\n",
    "                    if x != y:\n",
    "                        try:\n",
    "                            scoreOut = self.scorer(self.model, [respaced_sentences[x]], [respaced_sentences[y]])\n",
    "                            curDistance = parseScore(scoreOut)\n",
    "                        except:\n",
    "                            curDistance = -1\n",
    "                    else:\n",
    "                        curDistance = 1\n",
    "                    distance.append(curDistance)\n",
    "                distances.append(distance)\n",
    "            distances = parseDistances(distances)\n",
    "\n",
    "            #selection of best individuals\n",
    "            indices = sentenceSelection(respaced_sentences, scores, distances, self.rf)\n",
    "            \n",
    "            curRefined = []\n",
    "            for index in indices:\n",
    "                curRefined.append(respaced_sentences[index])\n",
    "            \n",
    "            curRefined = \" \".join(curRefined)\n",
    "            self.refined.append(curRefined)\n",
    "\n",
    "    def assess(self, verbose=True):\n",
    "        \"\"\"\n",
    "        Assesses quality of the refined corpus by computing Static BERTscore and Rouge-Score on the refined version compared to it's initial version.\n",
    "\n",
    "        :param1 self (Refiner): Refiner Object (see __init__ function for more details).\n",
    "        :param2 verbose (Boolean): When put to true, assess results will be printed.\n",
    "\n",
    "        :output (dict): Dictionnary containing both the scores of Static BERTScore and Rouge as well as their correlation\n",
    "        \"\"\"\n",
    "        assert self.refined != None, \"refined corpus doesn't exists\"\n",
    "\n",
    "        #Static BERTScore computation\n",
    "        scoreOut = self.scorer(self.model, self.refined, self.corpus)\n",
    "        customScore = [parseScore(curScore) for curScore in scoreOut]\n",
    "\n",
    "        #Rouge-Score computation\n",
    "        rougeScorer = rouge_scorer.RougeScorer(['rouge1', 'rougeL'], use_stemmer=True)\n",
    "        rougeScore = [rougeScorer.score(s, c) for s, c in zip(self.refined, self.corpus)]\n",
    "\n",
    "        #Data formating\n",
    "        custom_R = [round(t, 2) for t in customScore]\n",
    "        rouge1_R = [round(t['rouge1'][0], 2) for t in rougeScore]\n",
    "        rougeL_R = [round(t['rougeL'][0], 2) for t in rougeScore]\n",
    "\n",
    "        dfCustom = pd.DataFrame({'CBERT' : custom_R,\n",
    "                                'R-1' : rouge1_R,\n",
    "                                'R-L' : rougeL_R\n",
    "                                })\n",
    "\n",
    "        #Correlation estimation\n",
    "        pearsonCor_c_r1 = np.round(pearsonr(custom_R, rouge1_R), 2)\n",
    "        pearsonCor_c_rl = np.round(pearsonr(custom_R, rougeL_R), 2)\n",
    "\n",
    "        dfCor = pd.DataFrame({'pearson_CBERT_R-1' : pearsonCor_c_r1,\n",
    "                            'pearson_CBERT_R-L' : pearsonCor_c_rl}, index=[\"Pearson score\", \"p-value\"])\n",
    "\n",
    "        return {\"scores\": dfCustom, \"correlations\": dfCor}\n",
    "    \n",
    "    def __str__(self) -> str:\n",
    "        printout = \"--------REFINER OBJECT--------\\n\"\n",
    "        printout += \"Number of Documents : \" + str(len(self.corpus)) + \"\\n\"\n",
    "        printout += \"Corpus Avg Size     : \" + str(int(np.average([len(x) for x in self.corpus]))+1) + \"\\n\"\n",
    "        printout += \"Refined Avg Size    : \" + str(int(np.average([len(x) for x in self.refined]))+1) + \"\\n\"\n",
    "        printout += \"Reduction Factor    : \" + str(self.rf) + \"\\n\"\n",
    "        printout += \"Maximum Spacing     : \" + str(self.ms) + \"\\n\"\n",
    "        printout += \"------------------------------\"\n",
    "        return printout"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "w2v = serialized_to_model(r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Models\\serialized_w2v.pkl\")\n",
    "billsum0 = \"SECTION 1. SHORT TITLE.\\n\\n    This Act may be cited as the ``National Science Education Tax \\nIncentive for Businesses Act of 2007''.\\n\\nSEC. 2. CREDITS FOR CERTAIN CONTRIBUTIONS BENEFITING SCIENCE, \\n              TECHNOLOGY, ENGINEERING, AND MATHEMATICS EDUCATION AT THE \\n              ELEMENTARY AND SECONDARY SCHOOL LEVEL.\\n\\n    (a) In General.--Subpart D of part IV of subchapter A of chapter 1 \\nof the Internal Revenue Code of 1986 (relating to business related \\ncredits) is amended by adding at the end the following new section:\\n\\n``SEC. 45O. CONTRIBUTIONS BENEFITING SCIENCE, TECHNOLOGY, ENGINEERING, \\n              AND MATHEMATICS EDUCATION AT THE ELEMENTARY AND SECONDARY \\n              SCHOOL LEVEL.\\n\\n    ``(a) In General.--For purposes of section 38, the elementary and \\nsecondary science, technology, engineering, and mathematics (STEM) \\ncontributions credit determined under this section for the taxable year \\nis an amount equal to 100 percent of the qualified STEM contributions \\nof the taxpayer for such taxable year.\\n    ``(b) Qualified STEM Contributions.--For purposes of this section, \\nthe term `qualified STEM contributions' means--\\n            ``(1) STEM school contributions,\\n            ``(2) STEM teacher externship expenses, and\\n            ``(3) STEM teacher training expenses.\\n    ``(c) STEM School Contributions.--For purposes of this section--\\n            ``(1) In general.--The term `STEM school contributions' \\n        means--\\n                    ``(A) STEM property contributions, and\\n                    ``(B) STEM service contributions.\\n            ``(2) STEM property contributions.--The term `STEM property \\n        contributions' means the amount which would (but for subsection \\n        (f)) be allowed as a deduction under section 170 for a \\n        charitable contribution of STEM inventory property if--\\n                    ``(A) the donee is an elementary or secondary \\n                school described in section 170(b)(1)(A)(ii),\\n                    ``(B) substantially all of the use of the property \\n                by the donee is within the United States or within the \\n                defense dependents' education system for educational \\n                purposes in any of the grades K-12 that are related to \\n                the purpose or function of the donee,\\n                    ``(C) the original use of the property begins with \\n                the donee,\\n                    ``(D) the property will fit productively into the \\n                donee's education plan,\\n                    ``(E) the property is not transferred by the donee \\n                in exchange for money, other property, or services, \\n                except for shipping, installation and transfer costs, \\n                and\\n                    ``(F) the donee's use and disposition of the \\n                property will be in accordance with the provisions of \\n                subparagraphs (B) and (E).\\n        The determination of the amount of deduction under section 170 \\n        for purposes of this paragraph shall be made as if the \\n        limitation under section 170(e)(3)(B) applied to all STEM \\n        inventory property.\\n            ``(3) STEM service contributions.--The term `STEM service \\n        contributions' means the amount paid or incurred during the \\n        taxable year for STEM services provided in the United States or \\n        in the defense dependents' education system for the exclusive \\n        benefit of students at an elementary or secondary school \\n        described in section 170(b)(1)(A)(ii) but only if--\\n                    ``(A) the taxpayer is engaged in the trade or \\n                business of providing such services on a commercial \\n                basis, and\\n                    ``(B) no charge is imposed for providing such \\n                services.\\n            ``(4) STEM inventory property.--The term `STEM inventory \\n        property' means, with respect to any contribution to a school, \\n        any property--\\n                    ``(A) which is described in paragraph (1) or (2) of \\n                section 1221(a) with respect to the donor, and\\n                    ``(B) which is determined by the school to be \\n                needed by the school in providing education in grades \\n                K-12 in the areas of science, technology, engineering, \\n                or mathematics.\\n            ``(5) STEM services.--The term `STEM services' means, with \\n        respect to any contribution to a school, any service determined \\n        by the school to be needed by the school in providing education \\n        in grades K-12 in the areas of science, technology, \\n        engineering, or mathematics, including teaching courses of \\n        instruction at such school in any such area.\\n            ``(6) Defense dependents' education system.--For purposes \\n        of this subsection, the term `defense dependents' education \\n        system' means the program established and operated under the \\n        Defense Dependents' Education Act of 1978 (20 U.S.C. 921 et \\n        seq.).\\n    ``(d) STEM Teacher Externship Expenses.--For purposes of this \\nsection--\\n            ``(1) In general.--The term `STEM teacher externship \\n        expenses' means any amount paid or incurred to carry out a STEM \\n        externship program of the taxpayer but only to the extent that \\n        such amount is attributable to the participation in such \\n        program of any eligible STEM teacher, including amounts paid to \\n        such a teacher as a stipend while participating in such \\n        program.\\n            ``(2) STEM externship program.--The term `STEM externship \\n        program' means any program--\\n                    ``(A) established by a taxpayer engaged in a trade \\n                or business within an area of science, technology, \\n                engineering, or mathematics, and\\n                    ``(B) under which eligible STEM teachers receive \\n                training to enhance their teaching skills in the areas \\n                of science, technology, engineering, or mathematics or \\n                otherwise improve their knowledge in such areas.\\n            ``(3) Eligible stem teacher.--The term `eligible STEM \\n        teacher' means any individual--\\n                    ``(A) who is a teacher in grades K-12 at an \\n                educational organization described in section \\n                170(b)(1)(A)(ii) which is located in the United States \\n                or which is located on a United States military base \\n                outside the United States, and\\n                    ``(B) whose teaching responsibilities at such \\n                school include, or are likely to include, any course in \\n                the areas of science, technology, engineering, or \\n                mathematics.\\n    ``(e) STEM Teacher Training Expenses.--The term `STEM teacher \\ntraining expenses' means any amount paid or incurred by a taxpayer \\nengaged in a trade or business within an area of science, technology, \\nengineering, or mathematics which is attributable to the participation \\nof any eligible STEM teacher in a regular training program provided to \\nemployees of the taxpayer which is determined by such teacher's school \\nas enhancing such teacher's teaching skills in the areas of science, \\ntechnology, engineering, or mathematics.\\n    ``(f) Denial of Double Benefit.--No deduction shall be allowed \\nunder this chapter for any amount allowed as a credit under this \\nsection.''.\\n    (b) Conforming Amendments.--\\n            (1) Section 38(b) of such Code is amended by striking \\n        ``plus'' at the end of paragraph (30), by striking the period \\n        at the end of paragraph (31), and inserting ``, plus'', and by \\n        adding at the end the following new paragraph:\\n            ``(32) the elementary and secondary science, technology, \\n        engineering, and mathematics (STEM) contributions credit \\n        determined under section 45O.''.\\n            (2) The table of sections for subpart D of part IV of \\n        subchapter A of chapter 1 of such Code is amended by adding at \\n        the end the following new item:\\n\\n``Sec. 45O. Contributions benefiting science, technology, engineering, \\n                            and mathematics education at the elementary \\n                            and secondary school level.''.\\n    (c) Effective Date.--The amendments made by this section shall \\napply to taxable years beginning after the date of the enactment of \\nthis Act.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "r = Refiner([billsum0], w2v, score, 4)\n",
    "r.refine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "r.refined"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res =  r.assess()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"scores\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res[\"correlations\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(r)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Dynamic ratio"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from custom_score.utils import *\n",
    "from custom_score.score import score \n",
    "from rouge_score import rouge_scorer\n",
    "import bert_score\n",
    "import pandas as pd\n",
    "from scipy.stats import pearsonr\n",
    "from colorama import Fore, Style\n",
    "\n",
    "import sys\n",
    "sys.path.append(r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Supervised-Learning-using-Unsupervised-Learning-Metrics-in-the-absence-of-Annotated-Data\")\n",
    "from BARTScore.bart_score import BARTScorer\n",
    "\n",
    "class Refiner:\n",
    "\n",
    "    def __init__(self, corpus, model, scorer=score, ratio=2, threshold=0.70, maxSpacing=10, printRange=range(0, 1)):\n",
    "        \"\"\"\n",
    "        Constructor of the Refiner class. Aims at reducing the size and noise of a given independant list of documents.\n",
    "        \n",
    "        :param1 self (Refiner): Object to initialize.\n",
    "        :param2 corpus (List): List of documents to simplify.\n",
    "        :param3 model (Any): Model used to compute scores and create sentence's ranking.\n",
    "        :param4 ratio (float, int or array-like): Number determining how much the reference text will be shortened. \n",
    "        :param5 threshold (float): Number between 0 and 1 indicating the lowest acceptable quality when tuning the length of the summary.\n",
    "        :param6 maxSpacing (int): Maximal number of adjacent space to be found and suppressed in the corpus.\n",
    "        :param7 printRange (range): Range of corpus that should be displayed when the Refiner object in printed. \n",
    "        \"\"\"\n",
    "        self.corpus = corpus\n",
    "        self.processedCorpus = None\n",
    "        self.model = model\n",
    "        self.scorer = scorer\n",
    "        self.ratio = ratio\n",
    "        self.threshold = threshold\n",
    "        self.ms = maxSpacing\n",
    "        self.refined = None\n",
    "        self.printRange = printRange\n",
    "        self.selectedIndexes = None\n",
    "\n",
    "    def refine(self):\n",
    "        \"\"\"\n",
    "        Return a reduced string computed using static embedding vectors similarity. Also denoises the data by removing superfluous elements such as \"\\n\" or useless signs.\n",
    "\n",
    "        :param1 self (Refiner): Refiner Object (see __init__ function for more details).\n",
    "\n",
    "        :output refined (string): refined version of the initial document.\n",
    "        \"\"\"\n",
    "        self.refined = []\n",
    "        self.selectedIndexes = []\n",
    "        self.processedCorpus = []\n",
    "        for indiv in self.corpus:\n",
    "            #preprocess corpus\n",
    "            clean = cleanString(indiv, self.ms)\n",
    "            sentences = clean.split(\".\")\n",
    "            sentences.pop()\n",
    "            temp = []\n",
    "            for sentence in sentences: \n",
    "                if sentence != None and sentence != \"\":\n",
    "                    temp.append(sentence)\n",
    "            sentences = temp\n",
    "            respaced_sentences = []\n",
    "            for sentence in sentences:\n",
    "                if sentence[0] == \" \":\n",
    "                    sentence = sentence[1:]\n",
    "                respaced_sentences.append(sentence)\n",
    "            self.processedCorpus.append(respaced_sentences)\n",
    "\n",
    "            #compute ranking\n",
    "            scores = []\n",
    "            for sentence in respaced_sentences:\n",
    "                scoreOut = self.scorer(self.model, [sentence], [indiv])\n",
    "                R = parseScore(scoreOut)\n",
    "                scores.append(R)\n",
    "            \n",
    "            #compute distances\n",
    "            distances = []\n",
    "            for x in range(len(respaced_sentences)):\n",
    "                distance = []\n",
    "                for y in range(len(respaced_sentences)):\n",
    "                    if x != y:\n",
    "                        try:\n",
    "                            scoreOut = self.scorer(self.model, [respaced_sentences[x]], [respaced_sentences[y]])\n",
    "                            curDistance = parseScore(scoreOut)\n",
    "                        except:\n",
    "                            curDistance = -1\n",
    "                    else:\n",
    "                        curDistance = 1\n",
    "                    distance.append(curDistance)\n",
    "                distances.append(distance)\n",
    "            distances = parseDistances(distances)\n",
    "\n",
    "            #selection of best individuals\n",
    "            if type(self.ratio) == int or type(self.ratio) == float: \n",
    "                indices = sentenceSelection(respaced_sentences, scores, distances, self.ratio)\n",
    "            else:\n",
    "                for curRatio in sorted(self.ratio):\n",
    "                    curIndices = sentenceSelection(respaced_sentences, scores, distances, curRatio)\n",
    "                    subCurRefined = [respaced_sentences[i] for i in curIndices]\n",
    "                    scoreOut = score(self.model, [\" \".join(subCurRefined)], [indiv])\n",
    "                    curScore = parseScore(scoreOut)\n",
    "                    if curScore < self.threshold:\n",
    "                        try:\n",
    "                            indices = curBest\n",
    "                        except:\n",
    "                            indices = curIndices\n",
    "                        finally:\n",
    "                            break\n",
    "                    else:\n",
    "                        curBest = curIndices\n",
    "                if \"indices\" not in locals():\n",
    "                    indices = curIndices\n",
    "            indices.sort()\n",
    "            curRefined = []\n",
    "            for index in indices:\n",
    "                curRefined.append(respaced_sentences[index])\n",
    "            curRefined = \". \\n\".join(curRefined) + \".\"\n",
    "            self.selectedIndexes.append(indices)\n",
    "            self.refined.append(curRefined)\n",
    "\n",
    "    def assess(self, verbose=True):\n",
    "        \"\"\"\n",
    "        Assesses quality of the refined corpus by computing Static BERTscore and Rouge-Score on the refined version compared to it's initial version.\n",
    "\n",
    "        :param1 self (Refiner): Refiner Object (see __init__ function for more details).\n",
    "        :param2 verbose (Boolean): When put to true, assess results will be printed.\n",
    "\n",
    "        :output (dict): Dictionnary containing both the scores of Static BERTScore, BERTScore, BARTScore and Rouge as well as their correlation.\n",
    "        \"\"\"\n",
    "        assert self.refined != None, \"refined corpus doesn't exists\"\n",
    "\n",
    "        #Static BERTScore computation\n",
    "        scoreOut = self.scorer(self.model, self.refined, self.corpus)\n",
    "        customScore = [parseScore(curScore) for curScore in scoreOut]\n",
    "\n",
    "        #Rouge-Score computation\n",
    "        rougeScorer = rouge_scorer.RougeScorer(['rouge1', 'rougeL'], use_stemmer=True)\n",
    "        rougeScore = [rougeScorer.score(c, r) for c, r in zip(self.corpus, self.refined)]\n",
    "\n",
    "        #BERTScore computation\n",
    "        with nostd():\n",
    "            bertscore = bert_score.score(self.refined, self.corpus.to_list(), lang=\"en\", verbose=0)\n",
    "\n",
    "        #bartscore\n",
    "        bart_scorer = BARTScorer(device='cuda:0', checkpoint='facebook/bart-large-cnn')\n",
    "        bartscore = bart_scorer.score(self.corpus.to_list(), self.refined, batch_size=4)\n",
    "\n",
    "        #Data formating\n",
    "        custom_R = [round(t, 2) for t in customScore]\n",
    "        bertscore_R = [round(t.item(), 2) for t in bertscore[1]]\n",
    "        bartscore = [round(t, 2) for t in bartscore]\n",
    "        rouge1_R = [round(t['rouge1'][0], 2) for t in rougeScore]\n",
    "        rougeL_R = [round(t['rougeL'][0], 2) for t in rougeScore]\n",
    "\n",
    "        dfCustom = pd.DataFrame({'CBERT' : custom_R,\n",
    "                                 'BERTScore' : bertscore_R,\n",
    "                                 'BARTScore' : bartscore,\n",
    "                                 'R-1' : rouge1_R,\n",
    "                                 'R-L' : rougeL_R\n",
    "                                })\n",
    "\n",
    "        #Correlation estimation\n",
    "        pearsonCor_c_r1 = np.round(pearsonr(custom_R, rouge1_R), 2)\n",
    "        pearsonCor_c_rl = np.round(pearsonr(custom_R, rougeL_R), 2)\n",
    "        pearsonCor_bertscore_r1 = np.round(pearsonr(bertscore_R, rouge1_R), 2)\n",
    "        pearsonCor_bertscore_rl = np.round(pearsonr(bertscore_R, rougeL_R), 2)\n",
    "        pearsonCor_bartscore_r1 = np.round(pearsonr(bartscore, rouge1_R), 2)\n",
    "        pearsonCor_bartscore_rl = np.round(pearsonr(bartscore, rougeL_R), 2)\n",
    "\n",
    "        dfCor = pd.DataFrame({'pearson_CBERT_R-1' : pearsonCor_c_r1,\n",
    "                              'pearson_CBERT_R-L' : pearsonCor_c_rl,\n",
    "                              'pearson_BERT_R-1' : pearsonCor_bertscore_r1,\n",
    "                              'pearson_BERT_R-l' : pearsonCor_bertscore_rl,\n",
    "                              'pearson_BART_R-1' : pearsonCor_bartscore_r1,\n",
    "                              'pearson_BART_R-l' : pearsonCor_bartscore_rl}, index=[\"Pearson score\", \"p-value\"])\n",
    "        if verbose:\n",
    "            printout = \"Scores: \\n\"\n",
    "            printout += dfCustom.to_string() + \"\\n\\n\"\n",
    "            printout += \"Correlations: \\n\"\n",
    "            printout += dfCor.to_string()\n",
    "            print(printout)\n",
    "\n",
    "        return {\"scores\": dfCustom, \"correlations\": dfCor}\n",
    "    \n",
    "    def __str__(self) -> str:\n",
    "        printout = \"--------REFINER OBJECT--------\\n\\n\"\n",
    "        printout += \"Number of Documents : \" + str(len(self.corpus)) + \"\\n\"\n",
    "        printout += \"Corpus Avg Size     : \" + str(int(np.average([len(x) for x in self.corpus]))+1) + \"\\n\"\n",
    "        printout += \"Refined Avg Size    : \" + str(int(np.average([len(x) for x in self.refined]))+1) + \"\\n\"\n",
    "        printout += \"Ratio(s)            : \" + str(self.ratio) + \"\\n\"\n",
    "        printout += \"Threshold           : \" + str(self.threshold) + \"\\n\"\n",
    "        printout += \"Maximum Spacing     : \" + str(self.ms) + \"\\n\"\n",
    "        \n",
    "        self.printRange = self.printRange if self.printRange.start >= 0 and self.printRange.stop < len(self.processedCorpus) else range(0, len(self.processedCorpus))\n",
    "\n",
    "        for index in self.printRange:\n",
    "            printout += f\"\\nCorpus no.{index+1} : \\n\" + str(\".\\n\".join([f\"{Fore.LIGHTGREEN_EX}{self.processedCorpus[index][i]}{Style.RESET_ALL}\"\n",
    "                                                        if i in self.selectedIndexes[index]\n",
    "                                                        else f\"{Fore.RED}{self.processedCorpus[index][i]}{Style.RESET_ALL}\"\n",
    "                                                        for i in range(len(self.processedCorpus[index]))])) + \".\" + \"\\n\"\n",
    "        printout += \"\\n------------------------------\"\n",
    "        return printout"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test on Billsum"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SECTION 1. SHORT TITLE.\\n\\n    This Act may be...</td>\n",
       "      <td>National Science Education Tax Incentive for B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>SECTION 1. SHORT TITLE.\\n\\n    This Act may be...</td>\n",
       "      <td>Small Business Expansion and Hiring Act of 201...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>SECTION 1. RELEASE OF DOCUMENTS CAPTURED IN IR...</td>\n",
       "      <td>Requires the Director of National Intelligence...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text   \n",
       "0  SECTION 1. SHORT TITLE.\\n\\n    This Act may be...  \\\n",
       "1  SECTION 1. SHORT TITLE.\\n\\n    This Act may be...   \n",
       "2  SECTION 1. RELEASE OF DOCUMENTS CAPTURED IN IR...   \n",
       "\n",
       "                                             summary  \n",
       "0  National Science Education Tax Incentive for B...  \n",
       "1  Small Business Expansion and Hiring Act of 201...  \n",
       "2  Requires the Director of National Intelligence...  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "billsum_path = r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Datasets\\billsum\"\n",
    "billsum_test = pd.read_json(path_or_buf = billsum_path + r\"\\us_test_data_final_OFFICIAL.jsonl\", lines=True)\n",
    "billsum_test = billsum_test.loc[:, [\"text\", \"summary\"]]\n",
    "billsum_test.head(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2, 2)"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "subset = billsum_test.iloc[:2, :]\n",
    "subset.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "w2v = serialized_to_model(r'C:\\Pro\\Stages\\A4 - DVRC\\Work\\Models\\serialized_w2v.pkl')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "s = Refiner(subset[\"text\"], subset[\"summary\"], w2v, score, ratio=np.linspace(1, 3, 2), maxSpacing=15, printRange=range(0, 3))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "s.refine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>summary</th>\n",
       "      <th>processedText</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SECTION 1. SHORT TITLE.\\n\\n    This Act may be...</td>\n",
       "      <td>For purposes of section 38, the elementary and...</td>\n",
       "      <td>SECTION 1. SHORT TITLE. This Act may be cited ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>SECTION 1. SHORT TITLE.\\n\\n    This Act may be...</td>\n",
       "      <td>The number of retained workers taken into acco...</td>\n",
       "      <td>SECTION 1. SHORT TITLE. This Act may be cited ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text   \n",
       "0  SECTION 1. SHORT TITLE.\\n\\n    This Act may be...  \\\n",
       "1  SECTION 1. SHORT TITLE.\\n\\n    This Act may be...   \n",
       "\n",
       "                                             summary   \n",
       "0  For purposes of section 38, the elementary and...  \\\n",
       "1  The number of retained workers taken into acco...   \n",
       "\n",
       "                                       processedText  \n",
       "0  SECTION 1. SHORT TITLE. This Act may be cited ...  \n",
       "1  SECTION 1. SHORT TITLE. This Act may be cited ...  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s.RefinerToDataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "res = s.assess()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test on PubMed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from custom_score.refine import Refiner\n",
    "from custom_score.score import score\n",
    "from custom_score.utils import model_load"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>anxiety affects quality of life in those livin...</td>\n",
       "      <td>research on the implications of anxiety in par...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>small non - coding rnas are transcribed into m...</td>\n",
       "      <td>small non - coding rnas include sirna , mirna ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ohss is a serious complication of ovulation in...</td>\n",
       "      <td>objective : to evaluate the efficacy and safet...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>congenital adrenal hyperplasia ( cah ) refers ...</td>\n",
       "      <td>congenital adrenal hyperplasia is a group of a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>type 1 diabetes ( t1d ) results from the destr...</td>\n",
       "      <td>objective(s):pentoxifylline is an immunomodula...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text   \n",
       "0  anxiety affects quality of life in those livin...  \\\n",
       "1  small non - coding rnas are transcribed into m...   \n",
       "2  ohss is a serious complication of ovulation in...   \n",
       "3  congenital adrenal hyperplasia ( cah ) refers ...   \n",
       "4  type 1 diabetes ( t1d ) results from the destr...   \n",
       "\n",
       "                                             summary  \n",
       "0  research on the implications of anxiety in par...  \n",
       "1  small non - coding rnas include sirna , mirna ...  \n",
       "2  objective : to evaluate the efficacy and safet...  \n",
       "3  congenital adrenal hyperplasia is a group of a...  \n",
       "4  objective(s):pentoxifylline is an immunomodula...  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pm_path = r\"C:\\Pro\\Stages\\A4 - DVRC\\Work\\Datasets\\pubmed\\test.json\"\n",
    "pubmed_test = pd.read_json(pm_path, lines=True)\n",
    "pm = pubmed_test[[\"article_text\", \"abstract_text\"]]\n",
    "cleaner = lambda x: \". \".join(x).replace(\"<S>\", \"\").strip()\n",
    "\n",
    "pm.loc[:,\"abstract_text\"] = pm[\"abstract_text\"].replace(regex=r\"\\[[^\\]]*\\]\", value=\"\")\n",
    "pm.loc[:,\"article_text\"] = pm[\"article_text\"].replace(regex=r\"\\[[^\\]]*\\]\", value=\"\")\n",
    "pm.loc[:,\"abstract_text\"] = pm[\"abstract_text\"].map(cleaner)\n",
    "pm.loc[:,\"article_text\"] = pm[\"article_text\"].map(cleaner)\n",
    "pm = pm.rename(columns={\"article_text\":\"text\", \"abstract_text\":\"summary\"})\n",
    "pubmed = pm.copy()\n",
    "\n",
    "del pm \n",
    "del pubmed_test\n",
    "\n",
    "pubmed.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "lim = 10\n",
    "subset = pubmed.iloc[:lim, :]\n",
    "w2v = model_load(\"Word2Vec\", True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--------REFINER OBJECT--------\n",
      "\n",
      "Number of Documents : 10\n",
      "Corpus Avg Size     : 19030\n",
      "Refined Avg Size    : 4854\n",
      "Ratio(s)            : 4\n",
      "Threshold           : 0.7\n",
      "Maximum Spacing     : 10\n",
      "\n",
      "Corpus no.1 : \n",
      "\u001b[31manxiety affects quality of life in those living with parkinson 's disease ( pd ) more so than overall cognitive status , motor deficits , apathy , and depression [ 13 ] \u001b[0m.\n",
      "\u001b[31malthough anxiety and depression are often related and coexist in pd patients , recent research suggests that anxiety rather than depression is the most prominent and prevalent mood disorder in pd [ 5 , 6 ] \u001b[0m.\n",
      "\u001b[31myet ,\u001b[0m.\n",
      "\u001b[31mour current understanding of anxiety and its impact on cognition in pd , as well as its neural basis and best treatment practices , remains meager and lags far behind that of depression \u001b[0m.\n",
      "\u001b[31moverall , neuropsychiatric symptoms in pd have been shown to be negatively associated with cognitive performance \u001b[0m.\n",
      "\u001b[31mfor example , higher depression scores have been correlated with lower scores on the mini mental state exam ( mmse ) [ 8 , 9 ] as well as tests of memory and executive functions ( e\u001b[0m.\n",
      "\u001b[31mg\u001b[0m.\n",
      "\u001b[31m, attention ) [ 1014 ] \u001b[0m.\n",
      "\u001b[31mlikewise , apathy and anhedonia in pd patients have been associated with executive dysfunction [ 10 , 1523 ] \u001b[0m.\n",
      "\u001b[31mhowever , few studies have specifically investigated the relationship between anxiety and cognition in pd \u001b[0m.\n",
      "\u001b[31mone study showed a strong negative relationship between anxiety ( both state and trait ) and overall cognitive performance ( measured by the total of the repeatable battery for the assessment of neuropsychological status index ) within a sample of 27 pd patients \u001b[0m.\n",
      "\u001b[31mfurthermore , trait anxiety was negatively associated with each of the cognitive domains assessed by the rbans ( i\u001b[0m.\n",
      "\u001b[31me\u001b[0m.\n",
      "\u001b[31m, immediate memory , visuospatial construction , language , attention , and delayed memory ) \u001b[0m.\n",
      "\u001b[31mtwo further studies have examined whether anxiety differentially affects cognition in patients with left sided dominant pd ( lpd ) versus right sided dominant pd ( rpd ) ; however , their findings were inconsistent \u001b[0m.\n",
      "\u001b[31mthe first study found that working memory performance was worse in lpd patients with anxiety compared to rpd patients with anxiety , whereas the second study reported that , in lpd , apathy but not anxiety was associated with performance on nonverbally mediated executive functions and visuospatial tasks ( e\u001b[0m.\n",
      "\u001b[31mg\u001b[0m.\n",
      "\u001b[92m, tmt b , wms iii spatial span ) , while in rpd , anxiety but not apathy significantly correlated with performance on verbally mediated tasks ( e\u001b[0m.\n",
      "\u001b[31mg\u001b[0m.\n",
      "\u001b[31m, clock reading test and boston naming test ) \u001b[0m.\n",
      "\u001b[31mfurthermore , anxiety was significantly correlated with neuropsychological measures of attention and executive and visuospatial functions \u001b[0m.\n",
      "\u001b[31mtaken together ,\u001b[0m.\n",
      "\u001b[31mit is evident that there are limited and inconsistent findings describing the relationship between anxiety and cognition in pd and more specifically how anxiety might influence particular domains of cognition such as attention and memory and executive functioning \u001b[0m.\n",
      "\u001b[92mit is also striking that , to date , no study has examined the influence of anxiety on cognition in pd by directly comparing groups of pd patients with and without anxiety while excluding depression \u001b[0m.\n",
      "\u001b[31mgiven that research on healthy young adults suggests that anxiety reduces processing capacity and impairs processing efficiency , especially in the central executive and attentional systems of working memory [ 26 , 27 ] , we hypothesized that pd patients with anxiety would show impairments in attentional set shifting and working memory compared to pd patients without anxiety \u001b[0m.\n",
      "\u001b[92mfurthermore , since previous work , albeit limited , has focused on the influence of symptom laterality on anxiety and cognition , we also explored this relationship \u001b[0m.\n",
      "\u001b[31mseventeen pd patients with anxiety and thirty three pd patients without anxiety were included in this study ( see table 1 ) \u001b[0m.\n",
      "\u001b[31mthe cross sectional data from these participants was taken from a patient database that has been compiled over the past 8 years ( since 2008 ) at the parkinson 's disease research clinic at the brain and mind centre , university of sydney \u001b[0m.\n",
      "\u001b[31minclusion criteria involved a diagnosis of idiopathic pd according to the united kingdom parkinson 's disease society brain bank criteria and were confirmed by a neurologist ( sjgl ) \u001b[0m.\n",
      "\u001b[31mpatients also had to have an adequate proficiency in english and have completed a full neuropsychological assessment \u001b[0m.\n",
      "\u001b[31mten patients in this study ( 5 pd with anxiety ; 5 pd without anxiety ) were taking psychotropic drugs ( i\u001b[0m.\n",
      "\u001b[31me\u001b[0m.\n",
      "\u001b[31m, benzodiazepine or selective serotonin reuptake inhibitor ) \u001b[0m.\n",
      "\u001b[31mpatients were also excluded if they had other neurological disorders , psychiatric disorders other than affective disorders ( such as anxiety ) , or if they reported a score greater than six on the depression subscale of the hospital anxiety and depression scale ( hads ) \u001b[0m.\n",
      "\u001b[92mthus , all participants who scored within a depressed ( hads d > 6 ) range were excluded from this study , in attempt to examine a refined sample of pd patients with and without anxiety in order to determine the independent effect of anxiety on cognition \u001b[0m.\n",
      "\u001b[92mthis research was approved by the human research ethics committee of the university of sydney , and written informed consent was obtained from all participants \u001b[0m.\n",
      "\u001b[92mself reported hads was used to assess anxiety in pd and has been previously shown to be a useful measure of clinical anxiety in pd \u001b[0m.\n",
      "\u001b[92ma cut off score of > 8 on the anxiety subscale of the hads ( hads a ) was used to identify pd cases with anxiety ( pda+ ) , while a cut off score of < 6 on the hads a was used to identify pd cases without anxiety ( pda ) \u001b[0m.\n",
      "\u001b[31mthis criterion was more stringent than usual ( > 7 cut off score ) , in effort to create distinct patient groups \u001b[0m.\n",
      "\u001b[31mthe neurological evaluation rated participants according to hoehn and yahr ( h&y ) stages and assessed their motor symptoms using part iii of the revised mds task force unified parkinson 's disease rating scale ( updrs ) \u001b[0m.\n",
      "\u001b[31min a similar way\u001b[0m.\n",
      "\u001b[31mthis was determined by calculating a total left and right score from rigidity items 3035 , voluntary movement items 3643 , and tremor items 5057 from the mds updrs part iii ( see table 1 ) \u001b[0m.\n",
      "\u001b[31mprocessing speed was assessed using the trail making test , part a ( tmt a , z score ) \u001b[0m.\n",
      "\u001b[31mattentional set shifting was measured using the trail making test , part b ( tmt b , z score ) \u001b[0m.\n",
      "\u001b[31mworking memory was assessed using the digit span forward and backward subtest of the wechsler memory scale iii ( raw scores ) \u001b[0m.\n",
      "\u001b[31mlanguage was assessed with semantic and phonemic verbal fluency via the controlled oral word associated test ( cowat animals and letters , z score ) \u001b[0m.\n",
      "\u001b[31mthe ability to retain learned verbal memory was assessed using the logical memory subtest from the wechsler memory scale iii ( lm i z score , lm ii z score , % lm retention z score ) \u001b[0m.\n",
      "\u001b[31mthe mini mental state examination ( mmse )\u001b[0m.\n",
      "\u001b[31mdemographic , clinical , and neuropsychological variables were compared between the two groups with the independent t test or mann whitney u test , depending on whether the variable met parametric assumptions \u001b[0m.\n",
      "\u001b[31mchi square tests were used to examine gender and symptom laterality differences between groups \u001b[0m.\n",
      "\u001b[31mall analyses employed an alpha level of p < 0\u001b[0m.\n",
      "\u001b[31m05 and were two tailed \u001b[0m.\n",
      "\u001b[31mspearman correlations were performed separately in each group to examine associations between anxiety and/or depression ratings and cognitive functions \u001b[0m.\n",
      "\u001b[92mas expected , the pda+ group reported significant greater levels of anxiety on the hads a ( u = 0 , p < 0\u001b[0m.\n",
      "\u001b[92m001 ) and higher total score on the hads ( u = 1 , p < 0\u001b[0m.\n",
      "\u001b[31m001 ) compared to the pda group ( table 1 ) \u001b[0m.\n",
      "\u001b[31mgroups were matched in age ( t(48 ) = 1\u001b[0m.\n",
      "\u001b[92m31 , p = 0\u001b[0m.\n",
      "\u001b[31m20 ) , disease duration ( u = 259 , p = 0\u001b[0m.\n",
      "\u001b[31m66 ) , updrs iii score ( u = 250\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m65 ) , h&y ( u = 245 , p = 0\u001b[0m.\n",
      "\u001b[31m43 ) , ledd ( u = 159\u001b[0m.\n",
      "\u001b[92m5 , p = 0\u001b[0m.\n",
      "\u001b[31m80 ) , and depression ( hads d ) ( u = 190\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m06 ) \u001b[0m.\n",
      "\u001b[31madditionally , all groups were matched in the distribution of gender ( = 0\u001b[0m.\n",
      "\u001b[31m098 , p = 0\u001b[0m.\n",
      "\u001b[31m75 ) and side affected ( = 0\u001b[0m.\n",
      "\u001b[31m765 , p = 0\u001b[0m.\n",
      "\u001b[31m38 ) \u001b[0m.\n",
      "\u001b[31mthere were no group differences for tmt a performance ( u = 256 , p = 0\u001b[0m.\n",
      "\u001b[92m62 ) ( table 2 ) ; however , the pda+ group had worse performance on the trail making test part b ( t(46 ) = 2\u001b[0m.\n",
      "\u001b[31m03 , p = 0\u001b[0m.\n",
      "\u001b[31m048 ) compared to the pda group ( figure 1 ) \u001b[0m.\n",
      "\u001b[31mthe pda+ group also demonstrated significantly worse performance on the digit span forward subtest ( t(48 ) = 2\u001b[0m.\n",
      "\u001b[92m22 , p = 0\u001b[0m.\n",
      "\u001b[31m031 ) and backward subtest ( u = 190\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m016 ) compared to the pda group ( figures 2(a ) and 2(b ) ) \u001b[0m.\n",
      "\u001b[31mneither semantic verbal fluency ( t(47 ) = 0\u001b[0m.\n",
      "\u001b[31m70 , p = 0\u001b[0m.\n",
      "\u001b[31m49 ) nor phonemic verbal fluency ( t(47 ) = 0\u001b[0m.\n",
      "\u001b[31m39 , p = 0\u001b[0m.\n",
      "\u001b[31m70 ) differed between groups \u001b[0m.\n",
      "\u001b[31mlogical memory i immediate recall test ( u = 176 , p = 0\u001b[0m.\n",
      "\u001b[31m059 ) showed a trend that the pda+ group had worse new verbal learning and immediate recall abilities than the pda group \u001b[0m.\n",
      "\u001b[31mhowever , logical memory ii test performance ( u = 219 , p = 0\u001b[0m.\n",
      "\u001b[92m204 ) and logical memory % retention ( u = 242\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m434 ) did not differ between groups \u001b[0m.\n",
      "\u001b[31mthere were also no differences between groups in global cognition ( mmse ) ( u = 222\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m23 ) \u001b[0m.\n",
      "\u001b[31mparticipants were split into lpd and rpd , and then further group differences were examined between pda+ and pda\u001b[0m.\n",
      "\u001b[31mimportantly , the groups remained matched in age , disease duration , updrs iii , dde , h&y stage , and depression but remained significantly different on self reported anxiety \u001b[0m.\n",
      "\u001b[31mlpda+ demonstrated worse performance on the digit span forward test ( t(19 ) = 2\u001b[0m.\n",
      "\u001b[31m29 , p = 0\u001b[0m.\n",
      "\u001b[31m033 ) compared to lpda , whereas rpda+ demonstrated worse performance on the digit span backward test ( u = 36\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m006 ) , lm i immediate recall ( u = 37\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m008 ) , and lm ii ( u = 45\u001b[0m.\n",
      "\u001b[31m0 , p = 0\u001b[0m.\n",
      "\u001b[92m021 ) but not lm % retention ( u = 75\u001b[0m.\n",
      "\u001b[31m5 , p = 0\u001b[0m.\n",
      "\u001b[31m39 ) compared to rpda\u001b[0m.\n",
      "\u001b[31mthis study is the first to directly compare cognition between pd patients with and without anxiety \u001b[0m.\n",
      "\u001b[31mthe findings confirmed our hypothesis that anxiety negatively influences attentional set shifting and working memory in pd \u001b[0m.\n",
      "\u001b[92mmore specifically , we found that pd patients with anxiety were more impaired on the trail making test part b which assessed attentional set shifting , on both digit span tests which assessed working memory and attention , and to a lesser extent on the logical memory test which assessed memory and new verbal learning compared to pd patients without anxiety \u001b[0m.\n",
      "\u001b[31mtaken together ,\u001b[0m.\n",
      "\u001b[31mthese findings suggest that anxiety in pd may reduce processing capacity and impair processing efficiency , especially in the central executive and attentional systems of working memory in a similar way as seen in young healthy adults [ 26 , 27 ] \u001b[0m.\n",
      "\u001b[31malthough the neurobiology of anxiety in pd remains unknown , many researchers have postulated that anxiety disorders are related to neurochemical changes that occur during the early , premotor stages of pd related degeneration [ 37 , 38 ] such as nigrostriatal dopamine depletion , as well as cell loss within serotonergic and noradrenergic brainstem nuclei ( i\u001b[0m.\n",
      "\u001b[31me\u001b[0m.\n",
      "\u001b[31m, raphe nuclei and locus coeruleus , resp \u001b[0m.\n",
      "\u001b[31m, which provide massive inputs to corticolimbic regions ) \u001b[0m.\n",
      "\u001b[31mover time\u001b[0m.\n",
      "\u001b[31m, chronic dysregulation of adrenocortical and catecholamine functions can lead to hippocampal damage as well as dysfunctional prefrontal neural circuitries [ 39 , 40 ] , which play a key role in memory and attention \u001b[0m.\n",
      "\u001b[31mrecent functional neuroimaging work has suggested that enhanced hippocampal activation during executive functioning and working memory tasks may represent compensatory processes for impaired frontostriatal functions in pd patients compared to controls \u001b[0m.\n",
      "\u001b[31mtherefore , chronic stress from anxiety ,\u001b[0m.\n",
      "\u001b[31mfor example , may disrupt compensatory processes in pd patients and explain the cognitive impairments specifically in working memory and attention seen in pd patients with anxiety \u001b[0m.\n",
      "\u001b[31mit has also been suggested that hyperactivation within the putamen may reflect a compensatory striatal mechanism to maintain normal working memory performance in pd patients ; however , losing this compensatory activation has been shown to contribute to poor working memory performance \u001b[0m.\n",
      "\u001b[31manxiety in mild pd has been linked to reduced putamen dopamine uptake which becomes more extensive as the disease progresses \u001b[0m.\n",
      "\u001b[31mthis further supports the notion that anxiety may disrupt compensatory striatal mechanisms as well , providing another possible explanation for the cognitive impairments observed in pd patients with anxiety in this study \u001b[0m.\n",
      "\u001b[31mnoradrenergic and serotonergic systems should also be considered when trying to explain the mechanisms by which anxiety may influence cognition in pd \u001b[0m.\n",
      "\u001b[31malthough these neurotransmitter systems are relatively understudied in pd cognition , treating the noradrenergic and serotonergic systems has shown beneficial effects on cognition in pd \u001b[0m.\n",
      "\u001b[31mselective serotonin reuptake inhibitor , citalopram , was shown to improve response inhibition deficits in pd , while noradrenaline reuptake blocker , atomoxetine , has been recently reported to have promising effects on cognition in pd [ 45 , 46 ] \u001b[0m.\n",
      "\u001b[92moverall , very few neuroimaging studies have been conducted in pd in order to understand the neural correlates of pd anxiety and its underlying neural pathology \u001b[0m.\n",
      "\u001b[92mfuture research should focus on relating anatomical changes and neurochemical changes to neural activation in order to gain a clearer understanding on how these pathologies affect anxiety in pd \u001b[0m.\n",
      "\u001b[92mto further understand how anxiety and cognitive dysfunction are related ,\u001b[0m.\n",
      "\u001b[92mfuture research should focus on using advanced structural and function imaging techniques to explain both cognitive and neural breakdowns that are associated with anxiety in pd patients \u001b[0m.\n",
      "\u001b[31mresearch has indicated that those with amnestic mild cognitive impairment who have more neuropsychiatric symptoms have a greater risk of developing dementia compared to those with fewer neuropsychiatric symptoms \u001b[0m.\n",
      "\u001b[31mfuture studies should also examine whether treating neuropsychiatric symptoms might impact the progression of cognitive decline and improve cognitive impairments in pd patients \u001b[0m.\n",
      "\u001b[31mprevious studies have used pd symptom laterality as a window to infer asymmetrical dysfunction of neural circuits \u001b[0m.\n",
      "\u001b[31mfor example , lpd patients have greater inferred right hemisphere pathology , whereas rpd patients have greater inferred left hemisphere pathology \u001b[0m.\n",
      "\u001b[31mthus , cognitive domains predominantly subserved by the left hemisphere ( e\u001b[0m.\n",
      "\u001b[31mg\u001b[0m.\n",
      "\u001b[92m, verbally mediated tasks of executive function and verbal memory ) might be hypothesized to be more affected in rpd than lpd ; however , this remains controversial \u001b[0m.\n",
      "\u001b[31mit has also been suggested that since anxiety is a common feature of left hemisphere involvement [ 48 , 49 ] , cognitive domains subserved by the left hemisphere may also be more strongly related to anxiety \u001b[0m.\n",
      "\u001b[92mresults from this study showed selective verbal memory deficits in rpd patients with anxiety compared to rpd without anxiety , whereas lpd patients with anxiety had greater attentional / working memory deficits compared to lpd without anxiety \u001b[0m.\n",
      "\u001b[31malthough these results align with previous research , interpretations of these findings should be made with caution due to the small sample size in the lpd comparison specifically \u001b[0m.\n",
      "\u001b[92mrecent work has suggested that the hads questionnaire may underestimate the burden of anxiety related symptomology and therefore be a less sensitive measure of anxiety in pd [ 30 , 50 ] \u001b[0m.\n",
      "\u001b[31min addition , our small sample size also limited the statistical power for detecting significant findings \u001b[0m.\n",
      "\u001b[92mbased on these limitations , our findings are likely conservative and underrepresent the true impact anxiety has on cognition in pd \u001b[0m.\n",
      "\u001b[31madditionally , the current study employed a very brief neuropsychological assessment including one or two tests for each cognitive domain \u001b[0m.\n",
      "\u001b[92mfuture studies are encouraged to collect a more complex and comprehensive battery from a larger sample of pd participants in order to better understand the role anxiety plays on cognition in pd \u001b[0m.\n",
      "\u001b[31manother limitation of this study was the absence of diagnostic interviews to characterize participants ' psychiatric symptoms and specify the type of anxiety disorders included in this study \u001b[0m.\n",
      "\u001b[31mfuture studies should perform diagnostic interviews with participants ( e\u001b[0m.\n",
      "\u001b[31mg\u001b[0m.\n",
      "\u001b[92m, using dsm v criteria ) rather than relying on self reported measures to group participants , in order to better understand whether the type of anxiety disorder ( e\u001b[0m.\n",
      "\u001b[92mg\u001b[0m.\n",
      "\u001b[92m, social anxiety , phobias , panic disorders , and generalized anxiety ) influences cognitive performance differently in pd \u001b[0m.\n",
      "\u001b[31mone advantage the hads questionnaire provided over other anxiety scales was that it assessed both anxiety and depression simultaneously and allowed us to control for coexisting depression \u001b[0m.\n",
      "\u001b[92malthough there was a trend that the pda+ group self reported higher levels of depression than the pda group , all participants included in the study scored < 6 on the depression subscale of the hads \u001b[0m.\n",
      "\u001b[31mcontrolling for depression while assessing anxiety has been identified as a key shortcoming in the majority of recent work \u001b[0m.\n",
      "\u001b[92mconsidering many previous studies have investigated the influence of depression on cognition in pd without accounting for the presence of anxiety and the inconsistent findings reported to date , we recommend that future research should try to disentangle the influence of anxiety versus depression on cognitive impairments in pd \u001b[0m.\n",
      "\u001b[31mconsidering the growing number of clinical trials for treating depression , there are few if any for the treatment of anxiety in pd \u001b[0m.\n",
      "\u001b[92manxiety is a key contributor to decreased quality of life in pd and greatly requires better treatment options \u001b[0m.\n",
      "\u001b[31mmoreover , anxiety has been suggested to play a key role in freezing of gait ( fog ) , which is also related to attentional set shifting [ 52 , 53 ] \u001b[0m.\n",
      "\u001b[92mfuture research should examine the link between anxiety , set shifting , and fog , in order to determine whether treating anxiety might be a potential therapy for improving fog \u001b[0m.\n",
      "\n",
      "Corpus no.2 : \n",
      "\u001b[31msmall non coding rnas are transcribed into mrna but remain untranslated in eukaryotic cells \u001b[0m.\n",
      "\u001b[31mthey include sirna ( small interfering rna ) , mirna ( microrna ) , pirna ( piwi interacting rna ) and snorna ( small nucleolar rna ) \u001b[0m.\n",
      "\u001b[31mmirnas are a class of multifunctional singled stranded small rna which are ~20 nt in length and regulate the stability or translational efficiency of targeted messenger rna depending on the base pairing complementarity between the mirna and its target mrna [ 1 , 2 ] \u001b[0m.\n",
      "\u001b[31malthough over 1,000 mirna sequences have been identified from the tissues or cells of human origin and other species , as many as 1,000 to 10,000 mirnas per genome have been predicted [ 3 , 4 ] \u001b[0m.\n",
      "\u001b[31mmirnas regulate a broad range of biological processes including timing of development , cell cycle progression , stem cell self renewal , differentiation , cancer initiation , cancer cell proliferation , metastasis and apoptosis [ 511 ] \u001b[0m.\n",
      "\u001b[92mcancer is caused by multiple processes including uncontrolled cellular proliferation and inappropriate survival of apoptotic cells \u001b[0m.\n",
      "\u001b[31mmany regulatory factors switch on or off genes that govern cell division and direct cellular proliferation \u001b[0m.\n",
      "\u001b[31mmirnas regulate gene expression and play important roles in the onset and progression of tumorigenesis \u001b[0m.\n",
      "\u001b[31memerging evidence demonstrates the involvement of mirna in mammary gland tumorigenesis , functioning either as tumor suppressors or oncogenes \u001b[0m.\n",
      "\u001b[31malthough the current treatment of radiation therapy , chemotherapy and hormone therapy slow mammary gland tumor growth , prolong survival and improve the quality of patients life , metastatic breast cancer still remains incurable due to our limited understanding of the molecular mechanisms through which tumorigenesis and metastasis occur \u001b[0m.\n",
      "\u001b[31mas small non coding rnas regulate gene expression and tumorigenesis , they may represent a novel cancer therapy \u001b[0m.\n",
      "\u001b[31munlike mrna , mirnas are transcribed but never translated \u001b[0m.\n",
      "\u001b[92msome mirnas are transcribed from non coding regions between genes , deriving from independent transcription unit \u001b[0m.\n",
      "\u001b[31mother mirnas are transcribed together with coding mrnas from the coding region of the genome , deriving from the introns of gene transcripts [ 13 , 14 ] \u001b[0m.\n",
      "\u001b[31mmirna gene copy number gain / loss and mirna gene mutation have been observed in breast cancer resulting in the aberrant expression of mirna \u001b[0m.\n",
      "\u001b[31mthe first study about the altered expression of mirnas in human breast cancer patients and human breast cancer cell lines was reported in 2005 by lorio et al \u001b[0m.\n",
      "\u001b[31m,\u001b[0m.\n",
      "\u001b[31min which 29 mirnas were identified with aberrant expression based on microarray and northern blot analysis of 76 breast tumor samples and 14 human breast cell lines \u001b[0m.\n",
      "\u001b[31mzhang and colleagues analyzed 283 human mirna genes on 55 human breast primary tumors and 18 human breast cancer cell lines using array based comparative genomic hybridization \u001b[0m.\n",
      "\u001b[92mthe results demonstrated a high frequency ( ~72\u001b[0m.\n",
      "\u001b[31m8% ) of gene copy number abnormality in mirna containing regions in human breast cancer \u001b[0m.\n",
      "\u001b[31mwang et al \u001b[0m.\n",
      "\u001b[31mcollected 68 patients with newly diagnosed breast cancer and examined the expression of selected mirnas in tumor and adjacent non tumor tissues \u001b[0m.\n",
      "\u001b[31mmir21 , mir106a and mir155 were significantly over expressed in the tumor specimens compared with normal controls , whereas mir126 , mir199a and mir335 were significantly decreased in expression in the tumor samples \u001b[0m.\n",
      "\u001b[92mour studies of the mir17 92 cluster demonstrated decreased expression of mir17/20 in human breast cancer specimens compared with matching normal breast tissue from the same patient \u001b[0m.\n",
      "\u001b[31msubsequent analysis identified reduced mir17/20 expression in node positive compared with node negative breast cancers and demonstrated that mir17/20 inhibited breast cancer cell migration and invasion via a heterotypic signaling \u001b[0m.\n",
      "\u001b[31malthough the tendency for a global decrease of mirna expression in human cancers originally suggested a general tumor suppressor function of mirnas , subsequent studies showing the aberrant expression of specific mirnas in breast cancer suggest mirna specific roles in breast cancer onset and progression \u001b[0m.\n",
      "\u001b[31mmany distinct mirnas have been shown to regulate breast cancer cell proliferation , apoptosis , cancer stem cell expansion , and tumorigenesis \u001b[0m.\n",
      "\u001b[31mmirna may function as either tumor suppressors or oncogenes depending on the cell type , culture conditions , target genes and pathway \u001b[0m.\n",
      "\u001b[31mthe involvement of mirna in mammary gland tumorigenesis has been reviewed recently [ 21 , 22 ] \u001b[0m.\n",
      "\u001b[31mle et al \u001b[0m.\n",
      "\u001b[31mdescribed the expression pattern and regulatory network of key mirnas in breast cancer , including let7 , mir34 , mir125 , mir200 family , mir205 , mir21 , mir10 and the mir17 92 cluster \u001b[0m.\n",
      "\u001b[31madams et al \u001b[0m.\n",
      "\u001b[92mreviewed the mirna regulation of estrogen signaling pathway and erbb2/her signaling pathway in breast cancer \u001b[0m.\n",
      "\u001b[92mthe understanding of how mirnas are involved in breast cancer through regulating the cell cycle remains rudimentary \u001b[0m.\n",
      "\u001b[31mherein we summarize the recent literature and research progress on the mechanism by which mirnas regulate the breast cancer cell cycle and cellular proliferation ( fig \u001b[0m.\n",
      "\u001b[31m\u001b[0m.\n",
      "\u001b[31m1mirna regulation of mammary gland tumorigenesis in control of the cell cycle \u001b[0m.\n",
      "\u001b[92mthrough targeting different genes and different cyclin / cdk complexes , mir17/20 and\u001b[0m.\n",
      "\u001b[31mlet7 regulate the g1s transition ; mir21 and mir27a regulate the g2m checkpoint mirna regulation of mammary gland tumorigenesis in control of the cell cycle \u001b[0m.\n",
      "\u001b[31mthrough targeting different genes and different cyclin / cdk complexes , mir17/20 and\u001b[0m.\n",
      "\u001b[92mlet7 regulate the g1s transition ; mir21 and mir27a regulate the g2m checkpoint cyclin d1 is either overexpressed or amplified in ~50% of breast cancer \u001b[0m.\n",
      "\u001b[31mthe abundance of cyclin d1 is rate limiting in breast cancer cellular proliferation and g1s phase transition [ 23 , 24 ] \u001b[0m.\n",
      "\u001b[92min addition , cyclin d1 is a critical downstream target of erbb2 , ras and catenin induced breast cancers , and is sufficient for the induction of mammary tumors when targeted to the mammary gland of mice \u001b[0m.\n",
      "\u001b[31mantisense inhibition of cyclin d1 expression in vivo suppressed the growth of neut transformed mammary adenocarcinoma cells in nude mice \u001b[0m.\n",
      "\u001b[31mconserved sequences of the cyclin d1 3utr contain potential binding sites for multiple mirnas including mir17/20/106 , mir15/16 , mir23 and let7 \u001b[0m.\n",
      "\u001b[92mmir17/20 binds the cyclin d1 3utr , inhibiting the expression of cyclin d1 , resulting in cell cycle arrest at the g1 phase and suppression of mcf7 cell proliferation [ 18 , 26 ] \u001b[0m.\n",
      "\u001b[92mthe regulation of cyclin d1 expression by mir17 92 , as well as mir15/16 , was confirmed by deshpande et al \u001b[0m.\n",
      "\u001b[31m\u001b[0m.\n",
      "\u001b[31mthe let7 family functions as a tumor suppressor in a variety of cancers including lung , colon , ovarian and breast cancer \u001b[0m.\n",
      "\u001b[31mschultz et al \u001b[0m.\n",
      "\u001b[92mdemonstrated the downregulation of cyclin d1 by mirna let7 in control of cancer cell growth \u001b[0m.\n",
      "\u001b[31mthe regulation of cyclin d1 by mirna is likely of broad importance as cyclin d1 encodes the regulatory subunit of a kinase that phosphorylates and inactivates the prb family proteins to inhibit dna synthesis , and phosphorylates nuclear respiratory factor 1 ( nrf1 ) to inhibit mitochondria biogenesis [ 32 , 33 ] \u001b[0m.\n",
      "\u001b[31mfurthermore , cyclin d1 promotes breast epithelial cell angiogenesis and migration , and promotes chromosomal instability which in turn contributes to tumorigenesis \u001b[0m.\n",
      "\u001b[31mthe mir221/222 cluster regulates the cell cycle , cell growth and epithelial to mesenchymal transition ( emt ) in breast cancer \u001b[0m.\n",
      "\u001b[92mmir221/222 inhibited p27 and p57 abundance , facilitating g1s phase transition , thereby promoting cancer cell proliferation [ 36 , 37 ] \u001b[0m.\n",
      "\u001b[92mmoreover , mir221/222 may contribute to the aggressive clinical behavior of basal like breast cancers \u001b[0m.\n",
      "\u001b[31mthe breast cancer basal like subtype specific mirnas , mir221 and mir222 , promote emt in breast cancer by targeting trps1 ( trichorhinophalangeal syndrome type 1 ) which inhibits emt by repressing zeb2 expression \u001b[0m.\n",
      "\u001b[31mmir221 and/or mir222 expression in mcf7 and t47d breast cancer cells decreased er expression associated with tamoxifen resistance \u001b[0m.\n",
      "\u001b[31mthe onco mirna mir21 is overexpressed in a wide variety of cancers including breast cancer [ 40 , 41 ] \u001b[0m.\n",
      "\u001b[31mmir21 induced cellular proliferation , migration , invasion , emt , cancer stem cell characteristics and chemotherapy resistance in human breast cancer [ 42 , 43 ] \u001b[0m.\n",
      "\u001b[92mhigh mir21 level is associated with poor prognosis , advanced stage , positive lymph node status and reduced survival time in breast cancer \u001b[0m.\n",
      "\u001b[92mmir21 promotes mcf7 cellular proliferation in part through inhibiting the expression of a tumor suppressor gene programmed cell death 4 ( pdcd4 ) \u001b[0m.\n",
      "\u001b[31min colon cancer ,\u001b[0m.\n",
      "\u001b[31mmir21 participates in a dna damage induced g2m checkpoint through suppressing the cell cycle regulator cdc25a \u001b[0m.\n",
      "\u001b[92ma recent report demonstrated the mir21 regulates the cell cycle through targeting cdc25a in mcf7 breast cancer cells \u001b[0m.\n",
      "\u001b[31mwith a potential anti cancer chemical 3,3diindolylmethane treatment ,\u001b[0m.\n",
      "\u001b[92mmir27a expression is upregulated in human breast cancer cell lines \u001b[0m.\n",
      "\u001b[92min mda mb231 cells ,\u001b[0m.\n",
      "\u001b[31mmir27a negatively regulated the zinc finger zbtb10 gene and myt1 , thereby promoting breast cancer cell proliferation \u001b[0m.\n",
      "\u001b[92mmir27a suppressed myt1 , increased cdc2/cyclin b activity and promoted the g2m checkpoint in mda mb231 cells \u001b[0m.\n",
      "\u001b[31mthus , distinct mirnas affect key genetic targets that govern distinct cell cycle checkpoints including cyclins , cdks , cdk inhibitors and the g2m regulation apparatus \u001b[0m.\n",
      "\u001b[31min addition to cell cycle control , breast tumor onset and progression and breast tumor stem cells are also regulated by distinct mirnas \u001b[0m.\n",
      "\u001b[92mcancer stem cells ( cscs ) are characterized by their self renewal capacity , an ability to differentiate into non tumorigenic cell progeny , and their ability to seed tumors when transplanted into animal hosts \u001b[0m.\n",
      "\u001b[92mcell surface markers such as cd44 , cd24 , cd133 , epithelial specific antigen and aldehyde dehydrogenase1 are frequently used to isolate and enrich cscs \u001b[0m.\n",
      "\u001b[92mthe involvement of mirnas in regulating tumor formation by cscs or tumor initiating cells ( t ic ) has been widely investigated \u001b[0m.\n",
      "\u001b[31mlet7 expression is very low to undetectable level in embryonic stem cells ( es cells ) and increases with differentiation \u001b[0m.\n",
      "\u001b[31ma comparison of mirna expression between breast t ic and non t ic demonstrated reduced let7 expression in t ic and increased abundance with differentiation \u001b[0m.\n",
      "\u001b[31mtransduction of breast cscs with let7 reduced the proportion of undifferentiated cells , inhibited cell proliferation , mammosphere formation , and tumor formation in vivo \u001b[0m.\n",
      "\u001b[31mclarke and colleagues identified 37 mirnas which were differentially expressed between human breast cscs ( cd44cd24lineage ) and lineage nontumorigenic breast cancer cells \u001b[0m.\n",
      "\u001b[31mthe mir200 family members were downregulated in human breast cscs and normal mammary stem / progenitor cells \u001b[0m.\n",
      "\u001b[31mexpression of mir200 inhibited breast cancer stem cell expansion in vitro , and suppressed the tumor formation ability of human breast cancer stem cell in vivo \u001b[0m.\n",
      "\u001b[31mectopic mir34c expression reduced breast t ics self renewal , inhibited emt and suppressed tumor cell invasiveness via silencing notch4 \u001b[0m.\n",
      "\u001b[31mzhu et al \u001b[0m.\n",
      "\u001b[31mfound the reduced mir128 expression in human breast t ic was accompanied by bmi1 and abcc5 overexpression , and associated with chemotherapeutic resistance and poor survival \u001b[0m.\n",
      "\u001b[31menforced mir128 expression increased the sensitivity of breast cancer cells to doxorubicin induced apoptosis and dna damage \u001b[0m.\n",
      "\u001b[31memerging evidence has demonstrated the importance of cscs in cancer initiation , cancer metastasis and drug resistance \u001b[0m.\n",
      "\u001b[31mcscs are believed to be one of the most promising targets for cure of cancer \u001b[0m.\n",
      "\u001b[31mthe discovery that non coding rnas regulate cscs widens our understanding of cscs , and may provide potential novel strategies for breast cancer therapy \u001b[0m.\n",
      "\u001b[31mdeletion of chromosome 6q , including region 6q14q16 , is frequently observed in breast cancer \u001b[0m.\n",
      "\u001b[31mthe small non coding snorna u50 is a candidate tumor suppressor gene in the 6q14 16 region , playing a role in the development and/or progression of breast cancer \u001b[0m.\n",
      "\u001b[31mgenomic deletion and transcriptional downregulation of snorna u50 was detected in breast cancer cell lines \u001b[0m.\n",
      "\u001b[31mre expression of snorna u50 inhibited colony formation of the human breast cancer cells hs578 t and mda mb231 \u001b[0m.\n",
      "\u001b[31mpirnas are small non coding rna that form rna protein complexes through interactions with piwi proteins \u001b[0m.\n",
      "\u001b[92mpirna was initially discovered in germ line cells , and considered as germ line specific small rnas \u001b[0m.\n",
      "\u001b[31memerging evidence indicates that pirna expression occurs in somatic cells [ 57 , 58 ] and piwil2 expression has been identified in human breast cancer cells \u001b[0m.\n",
      "\u001b[31mhigh throughput deep sequencing identified a group of small rnas matching pirna sequences in human breast cancer tissues and breast cancer cell lines \u001b[0m.\n",
      "\u001b[31mthe study of these non coding small rnas in human cancer is just starting \u001b[0m.\n",
      "\u001b[31mthe identification of the expression signature of these non coding small rnas in breast cancer subtypes , and an understanding of their functional significance to oncogene expression , tumor initiation and tumor cell metastasis may shed important new perspectives on the role of these non coding small rnas in breast cancer \u001b[0m.\n",
      "\u001b[31msmall non coding rna based diagnostic and therapeutic applications for human cancer are expected in the near future \u001b[0m.\n",
      "\u001b[31malthough tumor targeted delivery and local administration are still major challenges to the practical application of gene therapy for cancer , mirna based cancer therapeutic approaches are being established and tested in animal models \u001b[0m.\n",
      "\u001b[92msynthetic mirna mimics or mirna expression vectors have been successfully applied to restore or overexpress mirna in vitro \u001b[0m.\n",
      "\u001b[31mchemically modified lna anti sense mirna inhibitor and other approaches have been used to block mirna function in cells \u001b[0m.\n",
      "\u001b[31mkim et al \u001b[0m.\n",
      "\u001b[31mrecently reported significant anti tumor effect of virus mediated delivery of mir145 combined with 5fu to treat breast cancer \u001b[0m.\n",
      "\u001b[92mintranasal delivery of let7 and intravenous delivery of mir34a mimics for non small cell lung cancer treatment and a virus mediated delivery of mir26a for liver cancer treatment in mouse model demonstrate the promise of mirna for treatment of cancer \u001b[0m.\n",
      "\u001b[92mdysregulated expression of mirnas has implicated components of the non coding genome as either oncogenes or tumor suppressors of breast cancer \u001b[0m.\n",
      "\u001b[31mexperimental evidence has shown specific mirnas regulating the initiation , progression , metastasis and drug resistance of breast cancer via control of the cell cycle , altering cellular proliferation , altering cellular apoptosis and/or controlling the population of tumor stem cells \u001b[0m.\n",
      "\u001b[92mdysregulated\u001b[0m.\n",
      "\u001b[92mmirna expression has also been observed in cancer associated fibroblasts ( caf ) and in the systemic circulation [ 65 , 66 ] \u001b[0m.\n",
      "\u001b[31mthe circulating mirnas have the potential to serve as novel diagnostic and prognostic biomarkers for breast cancer \u001b[0m.\n",
      "\u001b[92ma specific subset of dysregulated mirnas in breast cancer cells may serve as targets for gene therapy either alone or as an adjuvant treatment to current clinical protocols for breast cancer patients \u001b[0m.\n",
      "\n",
      "Corpus no.3 : \n",
      "\u001b[31mohss is a serious complication of ovulation induction , occurring in 1 10% of in vitro fertilization patients ( rizk and aboulghar , 1991 ; brinsden et al \u001b[0m.\n",
      "\u001b[31m, 1995 ) \u001b[0m.\n",
      "\u001b[31mthis iatrogenic condition has a spectrum of clinical and laboratory manifestations ranging from mild to severe , even life threatening conditions ( rizk et al \u001b[0m.\n",
      "\u001b[31m, 1990 ) \u001b[0m.\n",
      "\u001b[31mamong the serious manifestations of ohss are ascites and pleural effusion ( rizk and smitz , 1992 ) \u001b[0m.\n",
      "\u001b[31mvascular endothelial growth factor has emerged as one of the factors most likely involved in the pathophysiology of ohss ( geva and jaffe , 2000 ; rizk and aboulghar , 2010 ) \u001b[0m.\n",
      "\u001b[31mvascular endothelial growth factor is an angiogenic cytokine that is a potent stimulator of the vascular endothelium and appears to play an integral role in follicular growth , corpus luteum function and ovarian angiogenesis ( rizk et al \u001b[0m.\n",
      "\u001b[31m, 1997 ) \u001b[0m.\n",
      "\u001b[31mvascular endothelial growth factor causes increased capillary permeability with its sequelae of ascites and possible pleural effusion ( rizk et al \u001b[0m.\n",
      "\u001b[31m, 1997 ; gomez et al \u001b[0m.\n",
      "\u001b[31m, 2002 ) \u001b[0m.\n",
      "\u001b[31mhuman chorionic gonadotrophin is thought to play a crucial role in the development of ohss ( rizk et al \u001b[0m.\n",
      "\u001b[31mtwo distinct forms of severe ohss have been described : early and late forms ( papanikolaou et al \u001b[0m.\n",
      "\u001b[31m, 2005 ; mathur et al \u001b[0m.\n",
      "\u001b[31m, 2000 ) \u001b[0m.\n",
      "\u001b[92mearly ohss is caused by the administration of exogenous human chorionic gonadotrophin ( hcg ) and it starts before the 10th day after oocyte retrieval , while the late form is the result of endogenous human chorionic gonadotrophin release in the event of pregnancy , and it starts after the 10th day following oocyte aspiration ( papanikolaou et al \u001b[0m.\n",
      "\u001b[92m, 2005 ;\u001b[0m.\n",
      "\u001b[31msuch strategies included the use of low dose gonadotropins and frequent monitoring during controlled ovarian stimulation , cycle cancellation , coasting , freeze all embryos and the use of gonadotropin releasing hormone ( gnrh ) agonist as an oocyte trigger in gnrh antagonist cycles ( rizk et al \u001b[0m.\n",
      "\u001b[92mthe use of antagonist in the luteal phase with total freeze of embryos to prevent severe ohss has also been suggested ( lainas et al \u001b[0m.\n",
      "\u001b[31m, 2012 ) \u001b[0m.\n",
      "\u001b[31msuch strategies should be used especially in patients at high risk for developing severe ohss , including those who are young , have low body weight , have polycystic ovary syndrome , those who experience high estradiol levels , rapidly increasing estradiol levels , high number of follicles during controlled ovarian stimulation and those with high number of oocytes retrieved ( rizk and aboulghar , 1999 ; delvigne , 2009 ) \u001b[0m.\n",
      "\u001b[31mdopamine agonists have been proposed for the prevention of ohss in women at high risk \u001b[0m.\n",
      "\u001b[31mhowever , the study by lvarez et al \u001b[0m.\n",
      "\u001b[31m\u001b[0m.\n",
      "\u001b[92m( 2007 ) suggested that it was only effective in reducing the incidence of moderate ohss , but not in its severe form ( alvarez et al \u001b[0m.\n",
      "\u001b[31m, 2007 ) \u001b[0m.\n",
      "\u001b[31mlow dose aspirin therapy and doxycycline have also been suggested to inhibit angiogenesis ( fainaru et al \u001b[0m.\n",
      "\u001b[31m, 2009 ) \u001b[0m.\n",
      "\u001b[31m( 2011 ) believes that the concept of an ohss free clinic has become a reality \u001b[0m.\n",
      "\u001b[31mthe authors suggest that this approach should include pituitary down regulation using a gnrh antagonist , ovulation triggering with a gnrh agonist and vitrification of oocytes or embryos ( devroey et al \u001b[0m.\n",
      "\u001b[31m, 2011 ) \u001b[0m.\n",
      "\u001b[31msevere and critical forms of ohss are associated with significant ascites ( golan et al \u001b[0m.\n",
      "\u001b[31m, 1989 ; rizk et al \u001b[0m.\n",
      "\u001b[31m,\u001b[0m.\n",
      "\u001b[92mascites results in an increased abdominal pressure compromising venous return , cardiac output and renal perfusion ( navot et al \u001b[0m.\n",
      "\u001b[92mparacentesis is frequently needed , as prompt drainage of fluid produces a significant clinical and biochemical improvement , including spontaneous diuresis and hastening the resolution process ( rizk et al \u001b[0m.\n",
      "\u001b[31m, multiple paracenteses may be required to relieve symptoms and avoid serious sequelae of hemoconcentration , hypotension , decreased renal perfusion and severe respiratory compromise \u001b[0m.\n",
      "\u001b[31minstead of multiple interventions ,\u001b[0m.\n",
      "\u001b[31mthe placement of a catheter temporarily for a few days will permit complete drainage through one procedure ( rizk and aboulghar , 1999 ) \u001b[0m.\n",
      "\u001b[31mpigtail catheters have been used for drainage in various clinical situations \u001b[0m.\n",
      "\u001b[31min a previous study we described the use of percutaneous placement of a pigtail catheter for drainage of ascites caused by severe / critical ohss ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m, 2003 ) \u001b[0m.\n",
      "\u001b[31min this study we established the efficacy and safety of pigtail catheter drainage in the management of severe / critical ohss in patients who underwent in vitro fertilization and embryo transfer at our centre between 1999 and 2001 on both inpatient and outpatient basis \u001b[0m.\n",
      "\u001b[92mthe aim of the current study was to evaluate the role of the pigtail catheter drainage in outpatient management of patients with early onset severe ohss \u001b[0m.\n",
      "\u001b[31mthis is a retrospective study that included all patients who underwent in vitro fertilization and developed severe or critical ohss by the golan classification ( golan et al \u001b[0m.\n",
      "\u001b[31m, 1989 ) in the period between 2004 and 2009 \u001b[0m.\n",
      "\u001b[31mall patients underwent an ultrasound evaluation which documented the presence of severe ascites and bilateral ovarian enlargement \u001b[0m.\n",
      "\u001b[31mall patients presented with shortness of breath , marked abdominal distension , nausea , weight gain and lower abdominal pain \u001b[0m.\n",
      "\u001b[31mthirteen patients complained of vomiting , and 3 patients reported decreased urine output ( less than 720 cc per 24 hours ) and had haemoglobin 15 g / dl \u001b[0m.\n",
      "\u001b[31mall 33 patients were offered treatment using pigtail catheter insertion as an alternative to trans vaginal paracentesis \u001b[0m.\n",
      "\u001b[31mblood studies including a complete blood count , creatinine , electrolytes , serum albumin and total protein , and coagulation panel were ordered prior to the procedure \u001b[0m.\n",
      "\u001b[31mall 33 patients were rehydrated with intravenous crystalloid solutions ( 0\u001b[0m.\n",
      "\u001b[92m9% normal saline ) \u001b[0m.\n",
      "\u001b[31mcare was taken to give the patient the same amount of fluid as the amount that was drained from the peritoneal cavity \u001b[0m.\n",
      "\u001b[92m\u001b[0m.\n",
      "\u001b[31mall pigtail catheter placements were performed in the operating room at our surgical centre \u001b[0m.\n",
      "\u001b[31mthe catheter ( 6 0 french , 2\u001b[0m.\n",
      "\u001b[92m0 mm , boston scientific , quincy , ma , usa ) was introduced utilizing a non disposable metal gamete intra fallopian treatment ( gift ) trocar and cannula ( embryon gift catheter , ivf online , gilford , ct , usa ) which was introduced into the largest accessible ascitic fluid pocket in the upper outer quadrant of the abdominal wall under local anaesthesia and trans abdominal ultrasound guidance \u001b[0m.\n",
      "\u001b[31mthe trocar was then removed and a glide wire ( boston scientific corp \u001b[0m.\n",
      "\u001b[31m, watertown , ma , usa ) was threaded through the gift canula \u001b[0m.\n",
      "\u001b[31mthe canula was removed with care so as to keep the glide wire in the peritoneal cavity \u001b[0m.\n",
      "\u001b[31mthe pigtail catheter was guided into the peritoneal cavity by the wire after removal of the stylet of the pigtail catheter \u001b[0m.\n",
      "\u001b[31mthe catheter was anchored to the skin using 2 0 silk suture and it was supported by gauze , which was covered by a tegaderm \u001b[0m.\n",
      "\u001b[31mthe catheter was connected to a three way stop cock which was connected to a drainage bag \u001b[0m.\n",
      "\u001b[31minitial amount of drained fluid was calculated and subsequently the patients were trained to drain 1000 cc per day ( 500 cc in the morning and 500 cc in the evening ) \u001b[0m.\n",
      "\u001b[92mone liter normal saline and 500 cc of 6% hydroxyethyle starch solution ( hespan ) was administered to the patient on the same day of pigtail catheter placement \u001b[0m.\n",
      "\u001b[92many patient with critical ohss according to the golan classification , or those in whom the presenting symptoms and signs did not completely subside after drainage of ascitic fluid and iv fluid replacement , were admitted to the hospital for observation and further management \u001b[0m.\n",
      "\u001b[31mall other patients were sent home \u001b[0m.\n",
      "\u001b[31monce there was minimal or no drainage from the catheter , the patient returned to the office for removal of the catheter \u001b[0m.\n",
      "\u001b[31mthe patients were encouraged to drink plenty of fluids and to increase their protein intake \u001b[0m.\n",
      "\u001b[31mall patients kept a diary for body weight , abdominal girth , and urine output before and after the procedure \u001b[0m.\n",
      "\u001b[92mpatients were seen in the office as needed for evaluation and hydration with normal saline \u001b[0m.\n",
      "\u001b[31mdemographic data including mean age ( years ) , duration of infertility ( years ) , bmi ( kg / m2 ) and aetiology of infertility are illustrated in table i\u001b[0m.\n",
      "\u001b[31movarian stimulation data including number of treatment days , total dose of recombinant follicle stimulating hormone , hormone serum levels , endometrial thickness , number of follicles and number of patients receiving only 5000 iu of human chorionic gonadotrophin is illustrated in table ii \u001b[0m.\n",
      "\u001b[31mour data include the number of patients requiring early versus late placement of pigtail catheter , mean amount of ascitic fluid drained immediately after pigtail placement , number of days of pigtail catheter drainage and the number of days between oocyte retrieval and the onset of severe ohss symptoms requiring pigtail placement \u001b[0m.\n",
      "\u001b[31mtable iii also illustrates the number of patients who underwent coasting , number of patients who received prophylactic hespan on day of egg retrieval \u001b[0m.\n",
      "\u001b[92mvalues are expressed as mean + standard deviation values are expressed as mean + standard deviation : rfsh = recombinant fsh ; hmg = human menopausal gonadotropins ; hcg = human chorionic gonadotropin ; e2 = estradiol values are expressed as mean + standard deviation three patients ( 9% ) required an early placement of a pigtail catheter while 30 patients ( 91% ) had late placement of the catheter ( table iii ) \u001b[0m.\n",
      "\u001b[31mtwenty nine patients ( 88% ) were managed on an outpatient basis without any complications \u001b[0m.\n",
      "\u001b[92mfour patients ( 12% ) required hospital admission for 1 7 days ( 3 + 2\u001b[0m.\n",
      "\u001b[92m7 ) , three for associated severe pleural effusion requiring thoracentesis \u001b[0m.\n",
      "\u001b[31mthese three patients were admitted to the hospital immediately after insertion of the pigtail catheter for management of severe pleural effusion and careful observation \u001b[0m.\n",
      "\u001b[31mone patient was admitted 48 hours after insertion of the pigtail catheter for work up for chest pain , all tests were negative \u001b[0m.\n",
      "\u001b[31mnavot et al \u001b[0m.\n",
      "\u001b[31m, 1992 ; rizk and aboulghar , 1999 ) , but perhaps the most accepted classification of ohss is the one described by golan et al as mild , moderate and severe ( golan et al \u001b[0m.\n",
      "\u001b[31m, 1989 ) \u001b[0m.\n",
      "\u001b[92mhowever , clinicians should be aware that ohss is a dynamic condition and moderate ohss may progress to severe ohss within hours ( rizk and aboulghar , 1999 ; rizk , 2009 ) \u001b[0m.\n",
      "\u001b[92mtherefore , the practice committee of the american society for reproductive medicine ( asrm ) proposed a classification for ohss of mild , worsening and serious ( the practice committee of the american society for reproductive medicine , 2008 ) \u001b[0m.\n",
      "\u001b[31mrecognizing the patients at high risk , prevention and early recognition are the most important steps in the management of ohss ( rizk , 2006 ) \u001b[0m.\n",
      "\u001b[31mhowever , severe forms of ohss , especially late onset type that occurs when patients are pregnant , most likely will continue to happen , albeit at much lower rate , unless one reverts to a total freeze of all embryos after the use of gnrh agonist as a trigger shot in a gnrh antagonist cycle ( donoso and devroey , 2013 ; devroey et al \u001b[0m.\n",
      "\u001b[31m, 2011 ) \u001b[0m.\n",
      "\u001b[31mtraditional treatment consists mainly of supportive management until spontaneous resolution occurs ( rizk , 1994 ) \u001b[0m.\n",
      "\u001b[31malthough moderate ohss does not usually require intervention , outpatient monitoring is essential to identify progression to a severe form ( rizk , 2006 ) \u001b[0m.\n",
      "\u001b[92mpatients with moderate ohss can be managed on an outpatient basis by adequate hydration and close daily monitoring of weight gain and abdominal girth to detect progression to severe ohss , and to provide intervention , if required ( rizk , 2010 ) \u001b[0m.\n",
      "\u001b[92mpatients presenting with severe forms of ohss are usually managed on inpatient basis and most patients with critical ohss are admitted to intensive care units for aggressive supportive measures to avoid maternal morbidity and mortality ( the practice committee of the american society for reproductive medicine , 2008 ) \u001b[0m.\n",
      "\u001b[92mcorrection of hypovolemia , electrolyte imbalance and hypoalbuminemia are the basic principles during the treatment of severe ohss ( rizk , 1994 , 2006 ; myrianthefs et al \u001b[0m.\n",
      "\u001b[31m, 2000 ) \u001b[0m.\n",
      "\u001b[92m( 1992 ) suggested that paracentesis is the single most important treatment modality in life threatening ohss not controlled by medical therapy \u001b[0m.\n",
      "\u001b[31mparacentesis and removal of ascites result in relieving the pressure on the inferior vena cava and improvement in venous return , cardiac output and renal perfusion ( padilla et al \u001b[0m.\n",
      "\u001b[31m, 1990 ) \u001b[0m.\n",
      "\u001b[31mtherefore , prompt drainage of fluid produces significant clinical and biochemical improvement , including spontaneous diuresis and hastening the resolution process ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m, 2003 ; the practice committee of the american society for reproductive medicine , 2008 ) \u001b[0m.\n",
      "\u001b[31mit is also possible that removal of ascites decreases the amount of vegf and its effects on vascular permeability \u001b[0m.\n",
      "\u001b[92mtherefore ultrasound guided drainage of the ascitic fluid should be performed in severe cases of ohss with respiratory distress , oliguria or severe abdominal pain ( padilla et al \u001b[0m.\n",
      "\u001b[31m, 1990 ) \u001b[0m.\n",
      "\u001b[31mthis can be done either trans vaginally ( aboulghar et al \u001b[0m.\n",
      "\u001b[31m, 1990 ) or trans abdominally ( padilla et al \u001b[0m.\n",
      "\u001b[31m,\u001b[0m.\n",
      "\u001b[31m1990 ) \u001b[0m.\n",
      "\u001b[31mhowever , recurrence of ascites is common in severe cases of ohss \u001b[0m.\n",
      "\u001b[31mplacement of a pigtail catheter has been proposed by some investigators to allow drainage of ascitic fluid whenever it accumulates without the need for further surgical procedures ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m, 2003 ) \u001b[0m.\n",
      "\u001b[92min a previous study we reported the use of percutaneous pigtail catheter for drainage of ascites in severe ohss as an alternative to repeated paracentesis ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m, 2003 ) \u001b[0m.\n",
      "\u001b[31mthis procedure is relatively simple and requires a short period of time as compared to the time needed to gradually aspirate any fluid accumulation transvaginally \u001b[0m.\n",
      "\u001b[31mimmediate relief of symptoms and signs of severe ohss after pigtail catheter insertion was an important finding \u001b[0m.\n",
      "\u001b[31min addition , the ease by which any accumulated ascitic fluid was drained resulted in a faster resolution of ohss ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m,\u001b[0m.\n",
      "\u001b[31mno infection was reported ( abuzeid et al \u001b[0m.\n",
      "\u001b[31m, 2003 ) \u001b[0m.\n",
      "\u001b[31min that study the first 13 patients\u001b[0m.\n",
      "\u001b[31mthey were discharged home with the pigtail catheter in place and managed on an outpatient basis until ohss subsided ; thereafter the catheter was removed \u001b[0m.\n",
      "\u001b[92mthe last 13 patients were managed on an outpatient basis without any problem ( abuzeid mi , et al \u001b[0m.\n",
      "\u001b[31m, 2003 ) \u001b[0m.\n",
      "\u001b[31mour previous study confirmed the safety and effectiveness of the pigtail catheter for the management of severe ohss \u001b[0m.\n",
      "\u001b[31mtherefore , we embarked on the current study to evaluate the role of pigtail catheter drainage in outpatient management of patients with severe ohss syndrome \u001b[0m.\n",
      "\u001b[31min the current study we demonstrated that patients who were diagnosed very early with severe ohss can be managed safely and effectively on outpatient basis using pigtail catheter drainage , iv fluid replacement and careful monitoring \u001b[0m.\n",
      "\u001b[31malthough all 33 patients presented with shortness of breath , marked abdominal distension , nausea , weight gain and lower abdominal pain , and 13 of them complained of vomiting , ( all are criteria for hospital admission according to the practice committee of the american society for reproductive medicine on ohss ) , 30 patients were sent home as their presenting symptoms were relieved \u001b[0m.\n",
      "\u001b[92mearly diagnosis and intervention resulted in rapid elimination of the symptoms of severe ohss and normalization of vital signs , which allow us to manage the patients on outpatient basis \u001b[0m.\n",
      "\u001b[31mthe pigtail catheter placements were performed without complications and patients were discharged home after a few hours of observation \u001b[0m.\n",
      "\u001b[31mthe patients who needed hospital admission were those with associated severe pleural effusion requiring thoracentesis \u001b[0m.\n",
      "\u001b[31manother patient was admitted to the hospital for 1 day for work up for chest pain and possible diagnosis of pulmonary embolism \u001b[0m.\n",
      "\u001b[31monce pulmonary embolism was ruled out , she was discharged home with a pigtail catheter in place and she was managed on outpatient basis \u001b[0m.\n",
      "\u001b[31moutpatient management of ohss has no place in those who fail to have complete resolutions of their symptoms , or those with severe hyperproteinuria or electrolyte imbalance \u001b[0m.\n",
      "\u001b[31mcertainly it has no place in patients with critical ohss such as those with severe pleural effusion , diminished urine output , severe hemoconcentration and those at increased risk of thromboembolic risks ( rizk , 2010 ) \u001b[0m.\n",
      "\u001b[31mit is imperative to stress that such a protocol can only be used in patients who are motivated , reliable and have the necessary support at home to allow them to return to the clinic or go to the emergency room if the need arises \u001b[0m.\n",
      "\u001b[31mit also requires dedicated in vitro fertilization nurses to educate and follow up the patient on a daily basis \u001b[0m.\n",
      "\u001b[92mcontrary to other reports that state that access to intravenous albumin is a critical part of outpatient management for severe ohss , we did not use any albumin replacement ( lincoln et al \u001b[0m.\n",
      "\u001b[31m, 2002 ) \u001b[0m.\n",
      "\u001b[92mthe reason behind the use of intravenous albumin is to increase intravascular oncotic pressure , thereby curtailing the exodus of free water from the intravascular space \u001b[0m.\n",
      "\u001b[31min our study\u001b[0m.\n",
      "\u001b[31mwe used hespan instead of albumin , as some investigators have shown that it is beneficial in reducing the incidence of severe ohss ( youssef et al \u001b[0m.\n",
      "\u001b[31m, 2011 ) \u001b[0m.\n",
      "\u001b[31mby increasing the intravascular oncotic pressure\u001b[0m.\n",
      "\u001b[31min addition , the majority of our patients had late onset ohss as a result of pregnancy \u001b[0m.\n",
      "\u001b[92mhespan should be used with caution in patients with late onset ohss only when benefits outweigh risks\u001b[0m.\n",
      "\u001b[92mit is a fact that outpatient management of early severe ohss is a common practice among infertility specialists after trans vaginal aspiration of ascitic fluid and iv fluid hydration \u001b[0m.\n",
      "\u001b[31moutpatient management by repeated abdominal or trans vaginal paracentesis has been reported to be safe , effective and cost effective ( lincoln et al \u001b[0m.\n",
      "\u001b[31m, 2002 ; shrivastav et al \u001b[0m.\n",
      "\u001b[31m, 1994 ; fluker et al \u001b[0m.\n",
      "\u001b[31m, 2000\u001b[0m.\n",
      "\u001b[31m( 1994 ) were the first to suggest that day care management in patients with severe ohss with abdominal paracentesis and iv hydration was simple , safe and effective compared with traditional treatment with in patient hospitalization and supportive measures \u001b[0m.\n",
      "\u001b[31m( 2002 ) concluded that the need for hospitalization for hyperstimulated patients can be minimized by outpatient management of severe ohss with trans vaginal culdocentesis and rehydration with crystalloids and albumin \u001b[0m.\n",
      "\u001b[31m( 2000 ) advocated in a pilot study an active management strategy for moderate ohss , which involved early paracentesis designed to minimize the progression from moderate to severe ohss , instead of late paracentesis aimed at speeding up recovery in severely ill patients \u001b[0m.\n",
      "\u001b[31m( 2010 ) concluded that early outpatient paracentesis for moderate to severe ohss is the most cost effective management plan when compared with traditional conservative inpatient therapy \u001b[0m.\n",
      "\u001b[31m( 2009 ) reported a large series of patients with severe ohss in whom the vast majority were successfully managed as outpatients with use of aggressive trans vaginal paracentesis ( smith et al \u001b[0m.\n",
      "\u001b[31m, 2009 ) \u001b[0m.\n",
      "\u001b[31mdespite the findings in our study\u001b[0m.\n",
      "\u001b[31mit is important to emphasize that ohss remains a serious disorder with the potential for rapid deterioration , requiring hospitalization and intensive treatment of a critically ill patient \u001b[0m.\n",
      "\u001b[31mthe life threatening complications of ohss are secondary to thromboembolism or compromised pulmonary or cardiovascular function and multi organ failure\u001b[0m.\n",
      "\u001b[92m\u001b[0m.\n",
      "\u001b[31mthere have been isolated reports of women dying from the complications associated with ohss \u001b[0m.\n",
      "\u001b[92mthe mortality rate related to ohss is very low and was estimated by brinsden et al \u001b[0m.\n",
      "\u001b[31m\u001b[0m.\n",
      "\u001b[31mmore recently , reports regarding maternal mortality rates due to ohss in the netherlands and united kingdom demonstrate an incidence of approximately 3 deaths per 100,000 in ivf cycles ( braat et al \u001b[0m.\n",
      "\u001b[92m, 2006 ; lewis , 2007 ) \u001b[0m.\n",
      "\u001b[31meleven lethal complications of assisted reproductive technology have been documented and summarized by braat et al \u001b[0m.\n",
      "\u001b[31m\u001b[0m.\n",
      "\u001b[31mseveral investigators reported sporadic fatality as a result of ohss due to adult respiratory distress syndrome , massive pulmonary oedema , myocardial infarction , and carotid artery occlusion resulting in cerebral infarction \u001b[0m.\n",
      "\u001b[31min this study\u001b[0m.\n",
      "\u001b[31mwe describe a modified technique of what interventional radiologists usually use for pigtail catheter placement \u001b[0m.\n",
      "\u001b[31mwe observed that in the obese patients the metal introducer provided in the pigtail catheter kit is difficult to use ; instead we used the non disposable gamete intra fallopian treatment trocar and cannula to facilitate the introduction of the catheter through the abdominal wall of such patients \u001b[0m.\n",
      "\u001b[31mthis technique helps to manage the patients in the office without the need for sending her to the hospital for an interventional radiologist to place the catheter \u001b[0m.\n",
      "\u001b[31mhowever , the patients in this study were identified from our in vitro fertilization database ; the study included every patient who developed severe / critical ohss \u001b[0m.\n",
      "\u001b[31min addition , the lack of a control group that was managed without pigtail catheter placement limits the conclusions that can be drawn from our study \u001b[0m.\n",
      "\u001b[31min summary ,\u001b[0m.\n",
      "\u001b[31mdrainage of ascitic fluid in patients with severe / critical ohss is an important step in the management of this condition ( rizk , 2010 ) \u001b[0m.\n",
      "\u001b[92mthe placement of a pigtail catheter resulted in a safe and effective outpatient management of the majority of patients with severe ohss \u001b[0m.\n",
      "\u001b[31mhowever , outpatient management of this potentially fatal condition requires clear understanding that rapid deterioration may occur , which may necessitate hospitalization and intensive treatment of a critically ill patient ( rizk , 2006 , 2010 ) \u001b[0m.\n",
      "\u001b[31mpatients with critical ohss and those with persistence of symptoms of severe ohss despite insertion of a pigtail catheter and drainage of ascitic fluid should be admitted to the hospital for inpatient management \u001b[0m.\n",
      "\n",
      "------------------------------\n"
     ]
    }
   ],
   "source": [
    "r = Refiner(subset[\"text\"], subset[\"summary\"], w2v, score, 4, printRange=range(0, 3))\n",
    "r.refine()\n",
    "print(r)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at roberta-large were not used when initializing RobertaModel: ['lm_head.layer_norm.weight', 'lm_head.dense.weight', 'lm_head.decoder.weight', 'lm_head.bias', 'lm_head.dense.bias', 'lm_head.layer_norm.bias']\n",
      "- This IS expected if you are initializing RobertaModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing RobertaModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Scores: \n",
      "   CBERT  BERTScore  BARTScore   R-1   R-L\n",
      "0   0.85       0.84       0.30  1.00  1.00\n",
      "1   0.84       0.83       0.24  0.95  0.95\n",
      "2   0.85       0.85       0.30  1.00  1.00\n",
      "3   0.77       0.83       0.65  1.00  1.00\n",
      "4   0.86       0.83       0.38  0.99  0.98\n",
      "5   0.88       0.74       0.26  1.00  1.00\n",
      "6   0.84       0.84       0.48  1.00  1.00\n",
      "7   0.85       0.84       0.26  1.00  1.00\n",
      "8   0.88       0.82       0.30  0.99  0.99\n",
      "9   0.93       0.82       0.20  1.00  1.00\n",
      "\n",
      "Correlations: \n",
      "               pearson_CBERT_R-1  pearson_CBERT_R-L  pearson_BERT_R-1  pearson_BERT_R-l  pearson_BART_R-1  pearson_BART_R-l\n",
      "Pearson score               0.08               0.07             -0.07             -0.08              0.25              0.22\n",
      "p-value                     0.83               0.85              0.84              0.82              0.48              0.54\n"
     ]
    }
   ],
   "source": [
    "a = r.assess()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.3"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
